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This thesis is aiming to apply polymeric nanoparticle techniques to the gene therapy 
area. It combines principles from gene delivery, nanotechnology and polymer 
chemistry in order to improve the current polymeric vectors for gene delivery by 
investigating and evaluating the novel polymeric based gene delivery systems for 
plasmid DNA delivery as well as the delivery of short interference RNAi. 
 
Two independent research topics have been developed under the whole scheme of 
polymeric nanoparticles for gene delivery. One is about the evaluation of 
biodegradable nanoparticles as the RNAi gene delivery systems and the other one is 
regarding investigating the enhancement of polymer mediated gene transfection by 
co-administration of Vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate 
(Vitamin E TPGS).  
  
In my first research topic, biodegradable nanoparticles acted as the RNAi delivery 
vector. We constructed nanoparticles by two different biodegradable polymers 
formulated respectively from poly(D, L –lactide -co-glycolide) PLGA and Methoxy 
poly(ethylene glycol)-poly(lactide) (MPEG-PLA), with chitosan and 
poly(ethylenimine) (PEI) as the two surfactants modifying the surface of 
nanoparticles. By investigating both of the chemical and physical characterization of 
the four types of nanoparticles and conducting the biological assays, we evaluated and 
 vii
compared their capacities as the vector for carrying the double strand RNA (dsRNA) 
delivery system. Besides this, we also studied different nanoparticles fabrication 
methods to explore the best suitable one aiming to achieve the most highly 
transfection efficiency by optimizing the factors which affected the delivery process. 
Our final results show that PEI 25kd coating yielded the more positively charged 
nanoparticles with higher DNA binding capacity and higher in vitro gene transfection 
efficiency. MPEG-PLA/PEI nanoparticles with the smallest size demonstrated the 
highest transfection efficiency. 
 
We also extend the application of TPGS from traditional drug delivery to the gene 
delivery area by applying it in gene transfection. Our results show that it can enhance 
the transfection efficiency especially for some P-glycoprotein (P-gp) over expressing 
cells. Several cell lines, which include Polarized epithelial cells (Madin Darby canine 
kidney) MDCK, CaCO2 cells (a human colon adenocarcinoma cell line) and NIH 3T3 
(a mouse fibroblast cell line) cells, were transfected with PEI25kd/DNA complex 
blended with different concentrations of TPGS (PEI/TPGS). Transfection efficiency 
of those cells was proved to be several folds higher than pure PEI 25kd in a dose 
dependant manner. NIH3T3 cells were used as the negative control and were found no 
obvious enhancement. The results suggest that TPGS might be of great potential for 
the oral gene delivery and brain gene delivery because TPGS facilitate the 
DNA/vector complex to cross the gastrointestinal (GI) barrier and blood brain barrier, 
thus can benefit oral gene delivery and brain gene delivery.  
 viii
LIST OF FIGURES AND TABLES 
Fig.2.1 Basic components of cationic lipids (DC-Chol) and (DOTMA) 
Fig.2.2 Structure of the commonly used cationic polymers 
Fig.2.3 Dendrimer structure 
Fig.2.4 Structure of Linear and Branched PEI 
Fig.2.5 Strategies for the PEGylation of PEI/DNA polyplexes 
Fig.4.1. FESEM images of polymeric nanoparticles 
Fig.4.2 XPS spectrum of PLGA nanoparticles with PEI25kd coating a. the whole 
spectrum b. the nitrogen peak 
Fig.4.3. Gel electrophoresis of the RNA and nanoparticles 
Fig.4.4 Effects of SiRNA carried by four nanoparticles in PLC/PRF/5 cells 
Fig.4.5 Cell viability of nanoparticles in the PLC/PRF/5 cells after treatment with 
RNA/Polymer complex  
Fig.4.6 AFM image of PEI25kd/DNA complexes (N/P ratio=10:1) 
Fig.4.7 TPGS enhancement of PEI 25kd mediated gene transfection for MDCK cell 
lines  
Fig.4.8 Effect of TPGS enhancement on cellular uptake by MDCK CACO2, NIH3T3 
cells of polystyrene nanoparticles 
Fig.4.9 Cell cytotoxicity assay of TPGS mediated PEI/DNA complex 
Fig.4.10 GFP expression in MDCK cells after transfection  
Table 2.1 Ligands used to target PEI/DNA complexes 
 ix
Table 4.1 Size, zeta potential, of four PLGA nanoparticles with PEI25kd and chitosan 
surface modified   
Table.4.2 XPS analysis of surface element of PLGA nanoparticles and MPEG-PLA 
































LIST OF SYMBOLS 
PLGA             Poly (D, L –lactide-co-glycolide)                           
MPEG-PLA        Methoxy poly (ethylene glycol)-poly (lactide)     
PVA              Polyvinyl acetate                  
PEI               Poly(ethylenimine) 
PS               Polystyrene  
HBV             Hepatitis B virus 
CTL              Cytotoxic T lymphocyte 
HLA              Human leukocyte antigen 
HBsAg            Hepatitis B S antigen 
DsRNA            Double strand RNA 
SiRNA            short interference RNA 
FESEM            Field Emission Scanning Electron Microscopy 
AFM              Atomic Force Microscopy 
CLSM             Confocal laser scanning microscopy  
XPS               X-ray photoelectron spectroscopy 
ELISA             Enzyme-linked Immunosorbent Assay 
MTS              Mitochondrial reduction of tetrazolium salts into soluble dye 
PBS               Phosphate buffered saline 
DMEM             Dulbecco’s modified Eagle’s medium 
FBS               Fetal bovine serum 
 xi
DMSO             Dimethyl Sulfoxide 
BBB               Blood brain barrier 
GI                 Gastrointestinal barrier 
MDCK             Madin-Darby Canine Kidney 
HBSS              Hank’s balanced salt solution 
TPGS              Vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate 
GFP               Green fluorescent protein 
P-gp               P-Glycoprotein 
PTGS              Post-transcriptional gene silencing 
 1
Chapter 1 Introduction 
1.1 RNAi treatment for hepatitis B virus   
Hepatitis B is one of the major diseases and a serious public health problem in the 
world, especially in China. There are two billion people in the world who have been 
infected with the hepatitis B virus (HBV), and more than 350 million having life-long 
infections[1]. These chronically infected persons are at high risk of death from 
cirrhosis of the liver or even liver cancer, which kill about one million persons each 
year. Although Hepatitis B vaccine has been found 95% effective in preventing 
chronic infections from developing, it cannot cure chronic hepatitis. It is estimated 
that every year approximately a million people die from HBV related diseases 
worldwide [2]. 
 
Hepatitis B virus is a double stranded DNA virus and it causes chronic infection of 
liver because this virus can self replicate according to its template to form new viruses, 
which then infect the new hepatocytes [3]. The long time infection of this disease is 
the result of the interaction between the virus and the immune system of the host 
patient. The human cytotoxic T lymphocyte (CTL) mediated immune response 
against HBV antigen results in the apoptosis of the hepatocytes and thus leads to the 
permanent damage of human liver.  
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Many drugs have been developed in the treatment of chronic hepatitis B disease and 
among all the drugs, alfa-interferon (IFN-α) and lamivudine are the two most widely 
used drugs in clinical applications[4]. IFN-α possesses many ideal properties as the 
drug for chronic hepatitis B. It has both antiviral and immunomodulating effects. It 
may inhibit viral entry into hepatocytes; activate viral ribonuclease to inhibit HBV 
replication. It may also enhance CTL activity, stimulate natural killer cell activity and 
amplify human leukocyte antigen (HLA) class I protein on infected cells. However, 
IFN-α has poor therapeutic effect for those with higher HBV-DNA level and 
immunosuppressed patients. Lamivudine, acting as a directive antiviral agents, is a 
nucleoside analogue with potent inhibitory effects on HBV polymerase/reverse 
transcriptase activity[5]. Besides its profound suppressive effect, lamivudine may also 
restore the immune response of the patient to HBV and lamivudine treatment could 
overcome the CTL hypo responsiveness in chronic hepatitis B. The main 
disadvantage of this drug is the drug-resistance and drug durability because 
lamivudine therapy can only transiently block the synthesis of the new virus and 
prolong treatment is necessary for patients. One character of drug-resistance is the 
mutations of HBV which might emerge after six to nine months of lamivudine 
therapy and their occurrence incidence increases as the therapy time continues[6]. 
Recently, antisense technology of gene therapy brings hope to the treatment of 
hepatitis B diseases. Nucleic acid-based drugs, such as antisense 
oligodeoxynucleotides and ribozymes, provide another approach towards the 
treatment of chronic HBV infection.  
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Gene therapy is a rapidly advancing field with great potential for the treatment of 
diseases, which differs from other medical treatment by treating the cause of diseases 
rather than the symptoms [7]. Traditional gene therapy refers to the gene transfer into 
experimental animals or patients resulting in generalized or tissue-specific expression 
that may allow precise in-vivo manipulation of biological processes to cure diseases 
by directly removing their causes, that is, by correcting, adding and replacing the 
genes. Recently, with the development of current antisense therapeutic technology, 
short interference RNA (RNAi) as a new gene medicine show great potential for the 
successful treatment of cancer and some virus infected diseases. RNA interference 
(RNAi) is the process of endogenous cellular post transcriptional gene silencing 
induced by double stranded RNA that is homologous in sequence to the gene being 
suppressed [8]. RNA interference has been used as a research tool to control the 
expression of specific genes in numerous experimental organisms and has potential as 
a therapeutic strategy to reduce the expression of problem genes in many therapeutic 
systems since people first observed this phenomena in C. elegans [9]. People initially 
used long dsRNA and found it could induce the interferon response which would lead 
to the degradation and inhibition of mRNA translation [10, 11]. Subsequent study 
showed that the RNAi pathway involved the generation of an important sequence 
specific molecule which was called short interference RNA (siRNA) [12] and later on 
short interference RNA was shown to induce post-transcriptional gene silencing 
(PTGS) without causing any interferon response[11] and this has led to the 
widespread application of introducing chemically synthesized short interference RNA 
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to the target organisms. Recent progress demonstrated that chemically modified 
siRNA showed improved efficacy of siRNA and better persistence of in vivo activity. 
All these formal and current breakthrough shows that siRNA might be great potential 
for the clinically therapeutic approach. However, the therapeutic effect was hindered 
by the development of delivery systems.  
1.2 Vectors for RNAi delivery system  
Basically, ideal delivery systems should not only stabilize siRNA stabilization and 
protection against degradation through nucleases but also enhance their delivery into 
cells. In addition, such delivery vehicle should be administered efficiently, safely, and 
repeatable. Several efforts have investigated cationic lipids and polymers initially 
developed for plasmid DNA where internalization is by non-specific electrostatic 
interactions [13, 14] which is similar with traditional gene delivery strategy. However 
there is much difference between the two delivery strategies. Firstly, they have 
different delivery destinations: DNA delivery systems must overcome the nucleus 
barrier [15] to deliver their vehicle into cell nucleus; while as the exogenous delivery 
system, the task of RNAi delivery system is much easier because the RNA 
interference phenomena occurred outside cell nucleus.  Secondly, although both of 
these delivery systems utilize cationic agents, materials for the two delivery systems 
are different especially for the cationic polymers. However, current research into 
delivery of siRNA itself is still at a preliminary stage. There is little report in the 
literature concerning the RNAi delivery system. Most of the delivery systems people 
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used for RNAi delivery are from the gene delivery system such as the cationic 
liposome/lipid systems and cationic polymers. For example, lipofectamine 2000[16] 
is a commercially available cationic lipid which has been used for the RNAi delivery 
with high gene transfection efficiency for the in vitro assay. However, the toxic nature 
and poor in vivo performance and poor stability of this kind of cationic lipid made it 
impossible for its further application as the clinical drug delivery system. In order to 
increase the circulation time of the RNAi based drugs, polyethylene glycol (PEG) 
group was conjugated to the liposome for stealth property [17]. People also developed 
cationic polymers such as the low molecular weight poly(ethylenimine) (PEI) [18] 
with low cell cytotoxicity comparable to the branched higher molecular weight[19] 
PEI 25kd  because the synthetic siRNA is small enough to be condensed by the low 
charge density polymers.  
   
1.3 Biodegradable nanoparticles for RNAi delivery 
Recently, much attention was given to the application of polymeric nanoparticles to 
the drug and gene delivery because biodegradable nanoparticles can safely transport 
the genetic materials without exhibiting any toxicity and immune responses, and can 
be produced on a large scale. PLGA nanoparticles initially were mainly used to 
encapsulate the plasmid DNA by double emulsion technique after it was demonstrated 
to have the endolysosomal escaping property[19, 20]. Plasmid DNA entrapped in the 
PLGA core by this method showed a sustained release property[21]. Later on, another 
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strategy was developed that PLGA nanoparticles were modified by some cationic 
surfactants to display a positively charged surface allowing DNA binding on the 
surface of the nanoparticles through electrostatic interactions. These surfactants 
include cetyltrimethylammonium bromide (CTAB), poly(ethylenimine) (PEI), 
chitosan and poly(2-dimethylamino) ethyl methacrylate (pDMAEMA) polymers[22]. 
The cationic nanoparticles were shown to efficiently complex with DNA.  
1.4 TPGS application in drug delivery 
Vitamin E TPGS, d-a-tocopheryl polyethylene glycol 1000, as the only water-soluble 
derivative of Vitamin E, was initially used as a vitamin E supplement especially for 
patients with fat malabsorption syndromes [23-28].TPGS does not depend on fat 
absorption for uptake into intestinal cells due to its amphiphillic property because it 
has a relatively low critical micelle concentration, 0.02wt%, thus it could make the 
need for bile acids for vitamin E absorption eliminated by forming the micelle 
solutions at low concentrations[27]. Later on, TPGS was reported to function as an 
inhibitor of P-glycoprotein (P-gp), the multi drug resistance reporter [29-31] and 
TPGS was further used as an absorption and bioavailability enhancer for certain 
water-insoluble drugs. For example, researchers [32] demonstrated the effect of 
vitamin E-TPGS on the enhancement solubility and permeability of amprenavir, a 
potent HIV protease inhibitor. Researchers found a significant increase in 
cyclosporine (CsA) under the plasma concentration in-time-curve (AUC) when 
co-administered TPGS [33-36]; the co-administration of TPGS with many anticancer 
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drugs such as doxorubicin[29], vinblastine, paclitaxol, and colchicines also shows to 
enhance the cytotoxicity of these drugs. Recently development of TPGS tends to be 
the utilization as the surfactant [37-40] in some particulate and micelle [41]delivery 
systems for some anticancer drugs and protein drugs. All these results suggest that 
TPGS might be great potential as a novel adjuvant or surfactant in combination with 
an appropriate delivery system.  
1.5 TPGS inhibition of P-glycoprotein and its application in gene 
delivery 
Previous studies show that TPGS enhancement of drug absorption was probably 
mainly attributed to two reasons. One is its micelle formation would result in 
improved hydrophobic drug solubilization through its amphiphilic property , the other 
is due to its inhibition property of P-glycoprotein, which is confluent in many tissue  
including the intestine, liver, kidney, testis, placenta and endothelial cells comprising 
the blood brain barriers [42]. And P-glycoprotein, function as an ATP-dependent drug 
efflux pump in these tissues to remove chemically unrelated drugs, has also been 
implicated as a primary cause of multi drug-resistance in tumors [43]. Expressed on 
the apical surfaces of epithelial cells in major drug eliminating organs in the body, 
P-gp is responsible for secreting passively diffused drug out of the cell[44]. It uses 
energy gained from ATP hydrolysis to transport an assortment of structurally 
unrelated compounds out of cells. The drugs resisted by P-glycoprotein vary widely in 
their structure and people trying to propose hypothesis and set up models [45-48] to 
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understand the complex interactions that substrates and inhibitors have with the efflux 
transporter P-glycoprotein. People developed many substrates for P-glycoprotein and 
many inhibitors to bypass the efflux system, and so far the investigation about 
P-glycoprotein and its inhibitors showed that one common structural feature of these 
substrates identified for P-glycoprotein is their relatively hydrophobic, amphipathic 
nature [45, 46] and P-glycoprotein mainly limit passive permeability, that means 
P-glycoprotein limits absorption of only moderately permeable compounds[48, 
49].By inhibiting the resistance of P-glycoprotein, TPGS acting as the adjuvant in 
numerous delivery systems might enhance the permeable ability of nanoparticles 
containing drugs or drugs themselves. 
1.6 Objective 
In our present study, we tried to apply this strategy to the delivery of the dsRNA to 
evaluate its potential as the RNA delivery system. We have been investigating four 
types of biodegradable nanoparticles formulated respectively from poly(D, L 
–lactide-co-glycolide) PLGA and Methoxy poly(ethylene glycol)-poly(lactide) 
(MPEG-PLA), as the vector of double strand RNA delivery system. These 
nanoparticles were easily obtained by nanoprecipitation method and solvent 
evaporation technique and modified by the surface coating with cationic polymers. 
PEI and chitosan were chosen as the two surfactants because of their cationic property 
to bind the RNA on the surface of nanoparticles. Besides this, the presence of chitosan 
which was known for its recognized mucoadhesive and permeability enhancing 
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properties on the surface was supposed to increase the cellular uptake of nanoparticles 
[50].We also investigate the size effect on the RNA transfecion efficiency. The four 
types of cationic nanoparticles (PLGA/PEI, PLGA/chitosan, MPEG-PLA/PEI, and 
MPEG-PLA/chitosan) were compared with regards to chemical physical properties 
and RNA binding capabilities, cell cytotoxicity property and in vitro transfection 
efficiency. 
 
Furthermore, we have also studied the TPGS effect on the cellular uptake of 
polymer/DNA nanocomplexes and the effect on the gene transfection to 
P-glycoprotein positively expressed cells. Madine–Darby Canine kidney (MDCK), 
Caco-2 monolayer were used as cell models for the P-glycoprotein positively 
expressed cell lines in contrast with NIH3T3 cells which acted as the negative control. 
In this study, we utilized TPGS with different concentrations blending with PEI/DNA 
complex and found that the transfection efficiency for the P-glycoprotein positively 
expressed cells was improved significantly co administered with TPGS. Moreover, we 
further studied the TPGS enhancement for cellular uptake of polystyrene 
nanoparticles from the size 20nm to 500nm. The purpose of this study was mainly to 
understand the correlation of TPGS effect on the nanoparticles internalization with 
nanoparticles size and its effect on the epithelial permeability of those gene delivery 
vectors, which could aid in the future design of polymeric vehicles for gene delivery 
via the gastrointestinal tract. 
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1.7 Scope 
This thesis reports on the new application of polymeric nanoparticles on RNAi 
delivery systems and the investigation of TPGS as a gene transfection enhancer for 
the polymeric mediated gene transfection.  
 
Chapter 1 introduction presented the background and objective of this project. This 
thesis mainly focuses on the improvement of polymeric gene delivery system and the 
application of biodegradable nanoparticles to deliver the RNAi for hepatitis B virus. 
After introduction of a novel strategy RNAi for treating hepatitis B virus disease and 
the current challenge for RNAi delivery, the objective proposes a novel biodegradable 
polymeric delivery system and explores the enhancing property of TPGS for gene 
delivery. 
 
Chapter 2 reviewed related literature on gene delivery vectors including viral vectors 
and non-viral vectors which cover most of the current polymers for gene delivery. 
Finally, the author discussed the application of biodegradable nanoparticles for gene 
delivery which is viewed as the most promising field for current drug and gene 
delivery. Nanoparticulate delivery system is superior to traditional vectors in terms of 
biodegradability, ease of chemically modified property and sustained release property.  
. 
Chapter 3 described the detailed fabrication methods of cationic PLGA and 
MPEG-PLA nanoparticulate system, the thorough characterization techniques for the 
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physical and chemical property of nanoparticles, DNA loading experiment, and all the 
related cell experiments for evaluating the in vitro delivery performance of this 
nanoparticulate system. 
 
In Chapter 4, the results of two experiments were presented separately under the 
whole scheme of applying and improving the polymeric based gene delivery system. 
The results of nanoparticulate system for RNAi delivery show that our cationic 
MPEG-PLA/PEI nanoparticles can sufficiently bind with RNAi and effectively inhibit 
the production of virus protein, thus shows great potential for treating the hepatitis B 
virus disease. In the discussion part of the first experiment, the author also analyzed 
the physical property effect on the transfection efficiency such as size and zeta 
potential. The results of the other TPGS mediated gene transfection experiment show 
that DNA/polymer complex blending with TPGS can enhance the transfection 
efficiency especially for some P-glycoprotein (P-gp) over expressing cells. In the 
discussion of this experiment, the author discussed the possible reason of the 
enhancing property of TPGS and the further research is suggested to be done in order 
to explore more about the interaction between TPGS and P-gp and cellular uptake 
mechanism.  
 
Chapter 6 covers the conclusion and recommendation. The conclusion was drawn that 
this cationic biodegradable nanoparticle bears promising application in RNAi delivery 
and TPGS might be a good adjuvant for polymeric based gene delivery system.  In 
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the future recommendation, a serial of follow-up works were proposed including 
investigating the specific mechanism that how TPGS enhance the cellular uptake and 
transfection efficiency and applying the TPGS or TPGS-PLA copolymer synthesized 






























Chapter 2 Literature Review 
2.1 Gene therapy 
2.1.1 Overview of gene therapy 
Gene therapy is a rapidly advancing field with great potential for the treatment of 
diseases, which differs from other medical treatment by treating the cause of diseases 
rather than the symptoms. The diseases which have been most investigated in gene 
therapy to date are some genetic and acquired systemic diseases such as cancer and 
cardiovascular, pulmonary, and infectious diseases. As we know that, these diseases 
are generally the result of mutation or deletion of genes that impair normal biological 
mechanisms of human body. Gene transfer into experimental animals or patients 
resulting in generalized or tissue-specific expression may allow precise in-vivo 
manipulation of biological processes to cure these diseases described above by 
directly removing their causes, that is, by correcting, adding and replacing the genes.  
 
The basic challenge in gene therapy is to develop approaches to deliver genetic 
material to appropriate cells in a way that is specific, efficient, and safe. A naked DNA 
injection,[51, 52] without any carrier, into local tissues or into the systemic circulation 
is probably the simplest and safest ‘physical/mechanical’ approach. However, due to 
rapid degradation by nucleases and fast clearance by the mononuclear phagocyte 
system, the expression level, and the area of tissue treated, after a naked DNA 
injection are severely limited. Although some other physical methods for the delivery 
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of naked DNA have achieved some progress [53], there are still intracellular and 
extracellular barriers for naked plasmid DNA [54, 55] such as the electrostatic 
repulsion of cell membrane which would inhibit the entry of DNA into a cell. 
Furthermore, the degradation of the therapeutic DNA by serum nucleases is also a 
potential obstacle for functional delivery [56]. Therefore, a vector capable of 
protecting DNA must be used to deliver the nucleic acid because the success of gene 
therapy depends on the development of vehicles, known as vectors that can efficiently 
introduce the therapeutic genes into target cells. The progress in gene transfer 
technology, including viral and non-viral delivery vectors, has been made; however, 
an ideal vector system has not yet been constructed according to these problems. Here 
we call the process of gene delivery to specific cells or tissue organs and therapeutic 
protein expression to be transduction or transfection. Successful transduction requires 
overcoming a number of obstacles such as efficiency and targeting problems[57].  
 
2.1.2Hurdles for gene delivery 
 
The first challenging hurdle for gene therapy is the short-lived nature of gene therapy. 
The therapeutic DNA introduced into target cells must remain functional and the cells 
containing the therapeutic DNA must be long-lived and stable before gene therapy can 
become a permanent cure for any condition. The production problem of many rapidly 
dividing cells and the problem with integration therapeutic DNA into the genome 
prevents gene therapy from achieving longtime therapeutic functions. The second 
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issue is the problem of immune response of human body to the foreign therapeutic 
gene. Actually, the immune system is designed to attack any foreign object which is 
introduced into human tissues. The stimulation of the immune system would reduce 
gene therapy effectiveness and the immune system's enhanced response makes it 
difficult for repeating gene therapy in the same patients. This problem is common for 
many of the currently used vector systems and especially very severe for the viral 
vectors. Viruses, while the carrier of choice in most gene therapy studies due to its 
higher transfection efficiency comparable to non-viral vectors, present a variety of 
potential problems to the patient such as toxicity, immune and inflammatory 
responses, and gene control and targeting issues[55,56]. In addition, there is always 
the fear that the viral vector, once inside the patient, may recover its ability to cause 
disease. Finally the last issue we should concern is safety. When using integrating 
vector systems, it is important to consider the potential hazards of insertional 
mutagenesis, and thus vectors capable of site-specific integration will be attractive 
[57]. In many cases, expression of the therapeutic gene will require exquisite 
regulation [55], and thus the transcriptional unit must be capable of responding to 
manipulations of its regulatory elements. Finally, no pathogenic or adverse effects 
should be elicited by vector transduction, including undesirable immune responses 
[58].  
 
2.1.3 Systems for gene delivery 
According to these problems, we can summarize that vectors for gene delivery would 
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meet at least these following requirements. The first is the target ability for specific 
cells and tissue organs; the second is the protective ability of plasmid DNA; the third 
is the resistance to metabolic degradation and the avoidance of immune response, the 
forth is the safety issue especially for those using viral vectors; and the final issue is to 
the achievement of an efficient and regulated therapeutic way for diseases [53]. 
Furthermore, the ideal vectors should also have some other properties [58], for 
example, the delivery system should be easily produced at high titer on a commercial 
scale, and gene delivered by the vectors should achieve lifetime expression and can 
infect both dividing and non dividing cells.  
 
Current vectors that have been developed can mainly be divided into two broad 
categories: non-viral and viral vectors. They differ primarily in their assembling 
process. A viral vector is assembled in a cell, whereas a non-viral vector is constructed 
in a test tube. They are also called biological and non-biological systems. Each group 
has its own advantages and limitations[59]. 
 
2.2. Viral Vectors for gene delivery 
The basic concept of viral vectors is to harness the innate ability of viruses to deliver 
genetic material into the infected cells. Viral vectors are replication-defective viruses 
with part or all of the viral coding sequences replaced by that of therapeutic genes 
because viruses have the ability to gain access to specific cells and exploit the host’s 
cellular machinery to facilitate their replication. There is considerable interest in using 
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viruses for gene therapy because they could achieve sustained and highly efficient 
transfection level in gene delivery. The number of different viruses that are under 
development as vectors for gene therapy is steadily increasing. Major viral vectors 
mainly include retrovirus, adenovirus, herpes simplex virus (HSV), Adeno-associated 
virus (AAV), poxvirus (vaccina virus) and other chimeric viral vectors [59]. These 
viral-based vectors can be mainly separated in two general categories, integrating and 
non-integrating [60]. Among these many viral vectors, retroviral vectors are the only 
gene transfer systems that can mediate efficient integration of the transgene into 
recipient cells [60]. In contrast, the genome of vectors based on herpes (HSV), 
adeno-associated or adenovirus (AAV) vectors is maintained mainly as episomes. 
These do not usually integrate into the host genome and are consequently lost over 
time. Therefore, expression from non-integrating vectors is often transient, especially 
in tissues or organs with a high cellular turnover. Most of these viral vectors except 
the adenovirus factors can transfect both dividing and none dividing cells. This 
property, on one hand, rendered the higher transfection level both in vitro and in vivo 
comparable to the non-viral vectors; on the other hand, both the original pathologic 
and latent infectious nature of these viruses can limit their therapeutic applications 
[59]. The immunogenicity and cytotoxicity caused by the viral vectors are the main 
drawbacks of using virus as the delivery system. People found an inflammatory 
reaction of the adenovirus vector [61, 62] and another phenomenon known as 
insertional mutagenesis which will lead to malignant transformation of cells in the 
patient[63]. These drawbacks suggest that viral-based vectors urgently need to be 
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reassessed with regard to their safety for human gene therapy [64]. 
2.3 Non-Viral Vectors 
2.3.1 Barriers for gene delivery system 
The other commonly used gene delivery system is the non biological gene delivery 
system which can also be called non-viral vectors. Generally speaking, recently 
developed synthetic non-viral vectors can be formed by associating the nucleic acid 
sequences with cationic lipids or cationic polymers to form lipoplexes or polyplexes.  
These cationic non-viral delivery systems interact with DNA to assist cell entry by 
binding or enveloping DNA through a charge interaction. This interaction will 
condense and protect plasmid DNA (pDNA) from premature degradation during 
storage and transportation from the site of administration to the site of gene 
expression. The sequence of events involved in cationic transfection reagent mediated 
gene transfer include: (1) the formation of the DNA/Lipid or DNA/ Polymer complex; 
(2) the complex bind to the negative charges on the surface of cells; (3) internalized 
through a vesicular pathway; (4) the escape of DNA from the endosome; (5) entry of 
DNA into the nucleus followed by gene expression [65-69]. This brings up the 
requirements of non-viral vectors as follows: in order to protect the DNA until it 
reaches its target, the non-viral delivery systems must be small enough to allow 
internalization into cells and passage to the nucleus, it must have flexible tropisms for 
applicability in a range of disease targets, and it must be capable of escaping 




2.3.2 Cationic lipsomes 
Cationic liposome constructed by phospholipid bubbles with the structure of bilayered 
membrane have attracted a lot of attention since [71] the discovery of DOTMA- a 
kind of cationic lipid in 1987 which could efficiently deliver the gene. From then on, 
many cationic lipids have been utilized as pharmaceutical gene carriers due to their 
simplicity and highly biocompatible property [72]. Lipids in aqueous systems can 
easily form spherical, self-closed structure which is commonly called liposome. 
Liposome usually consists of one or several concentric lipid bilayers with an aqueous 
phase inside and between the lipid bilayers [73]. In aqueous system, liposome with 
hollow spheres can easily encapsulate DNA in their aqueous centers through 
electrostatic interaction. Most cationic lipids used as gene transfection reagents have 
mainly three parts which include a hydrophobic lipid anchor group, a linker group, 
such as an ester, amide or carbamate, and a positively charged head-group.  
Hydrophobic group lipid anchors are known to affect transfection efficiency, such as 
cholesterol [74] and its derivatives. The linker group is an important component, 
which determines the chemical stability and biodegradability of the lipid; the cationic 
group have the ability to interact with the plasmid DNA [65], leading to the 
condensation of the DNA (Fig2.1) [75, 76].This structure property offers much 
flexibility for researchers to design their own specific cationic lipid for gene delivery 
by choosing proper lipid groups according to their purpose. Permanent search for the 
design of new cationic lipids is conducted for creation of efficient gene delivery 
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systems [77].  
 
  
Fig.2.1 Basic components of cationic lipids 3-â[N(N′,N′-dimethylaminoethane) 
-carbamoyl] cholesterol (DC-Chol) and N-[1-(2,3-dioleyloxy)propyl]-N,N,N- 
trimethylammonium chloride (DOTMA).[76] (a) Hydrophobic lipid group; (b) linker 
group; (c) cationic headgroup.  
Comparable with the viral vector, cationic lipids have their own distinct advantage 
such as robust manufacture ability, ease in handling & preparation techniques, target 
ability, large-scale production and low immunogenic response [78]. However, there 
are several limitations of cationic liposome inhibiting its clinical application which 
are closely connected to a short lifetime of the complexes, as well as to their 
inactivation by serum proteins and toxicity of cationic lipids in high concentrations 
[65]. Most cationic lipid/plasmid complexes are toxic, activate the complement 
systems and do not disperse well inside the target tissues[66]. 
2.3.3 Cationic polymers 
Another polycationic vectors which have been most extensively used in clinical 
studies were the cationic polymers based vectors. Similar to the cationic lipid, cationic 
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polymers display striking advantages as vectors for gene delivery. However, 
comparable to lipoplex, one of the distinct advantage of polyplex is its stability and 
more suitable for long time storage by lyophilization. They can be specifically 
tailored for the proposed application by choosing appropriate molecular weights, 
coupling of cell or tissue specific targeting moieties and/or performing other 
modifications that confer upon them specific physiological or physicochemical 
properties. All the cationic polymers contain high densities of primary amines and are 
protonatable at neutral pH, which facilitate the endo-lysosomal escape of these 
polymers during the transfection process. This high density of positive charges allows 
the cationic polymers to form stable complexes with negative charged plasmid DNA 
or other oligonucleotides in a self assemble way. The polyplex constructed by cationic 
polymers with DNA also generate nanosized structures which facilitate the cellular 
uptake. Furthermore, the prime amine groups can be chemically modified with 
ligands and peptides that can enhance the transfection process, entitled the polymer 
targeting ability and decrease the cytotoxicity of polymers. Some frequently used 
cationic polymers include poly(L-lysine) (PLL), polyethyleneimine (PEI), 
polyamidoamine dendrimers (PAMAM), gelatins, chitosan, and Fig 2.2 shows their 
structures. These polymers vary widely in their structures, which range from linear to 
highly branched molecules and influence their complexation with nucleic acids and 




2.4 Typical cationic polymeric vectors for gene delivery 
2.4.1 Poly (L-lysine)-based vectors 
Poly(L-lysine) (PLL) was the first polycation characterized and recognized as a 
potential polymeric vectors used for non-viral gene delivery [79]. So far, people have 
already demonstrated their capability for both in vitro and in vivo gene delivery [80]. 
They are linear polypeptides with the amino acid lysine as the repeat unit; thus, they 
posses a biodegradable nature. Typically polylysine comes in a variety of sizes, and is 
usually specified as the average number of polylysine molecules within a defined 
solution rather than a specifically defined number of lysine molecules per polylysine 
molecule. In order to circumvent this heterogenecity problem, researchers generally 
synthesize these polymers on a solid support using a series of protecting/ 
de-protecting synthetic steps. For example, researchers use 
fluoren-9-ylmethoxy-carbonyl chemistry to obtain mono-disperse peptides [81]. And 



































Fig.2.2. Structure of the commonly used cationic polymers 
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PLL based vectors with the amino group of lysine could form complex with DNA 
easily through charge interaction, the preparation procedure for complex formation 
can influence transfection efficiency. Various methods have been developed to 
generate protocols that consistently and repeatedly generate predefined 
polylysine/DNA complexes of defined stability and size, such as flash mixing [84], 
high-salt conditions followed by dialysis[85, 86], or high salt and vigorous 
agitation[86, 87]. These various methods generate polylysine/DNA complexes of 
between 15 and 30nm, 50 and 150nm [10].  PLL is typically used at charge ratios 
(N/P) ranging from 3:1 to 6:1. As increasing amounts of PLL are added to DNA, the 
structure of the polyplex changes from circular to thick, flattened to compact, and 
finally to toroids and rods at a charge ratio of 6:1 [88].The diameter and cross section 
of the toroids are approximately 140 and 44 nm, respectively [88]. There is a dilemma 
for ideal length of the PLL because it needs to find a balance between two competing 
effects: effective condensation and cytotoxicity. High molecular weight PLL tends to 
form smaller condensates and shows higher gene transfection efficiency but the 
cytotoxicity is also higher than the low molecular weight PLL [89]. 
 
Among all the cationic polymers used for gene delivery, PLL has poor transfection 
ability when applied alone [90]. The co-application of chloroquine, a lysosomotropic 
agent, was shown to increase the transfection efficiency of PLL [90]. Another 
approach to increase its gene transfection efficiency is to create the desirable proton 
sponge effect similar to that of PEI polyplexes by introducing histidine residues to 
 25
PLL backbone [91, 92]. Researchers also use the common strategy of chemical 
modification methods including coating with PEG, and targeting ligands in order to 
prolong the circulation time and optimize the transfection.   
 
2.4.2 Dendrimer 
Dendrimers started to draw people’s attention as a new gene transfer vector in the late 
1970s and early 1980s. People have been attracted by their unique properties of highly 
branched three dimensional structures and robust chemical property for over three 
decades.  Dendritic structures emerged from a new class of polymers named 
“cascade molecules” [93, 94] and developed further to the larger dendritic structures 
[95-97]. These hyper-branched molecules were called “dendrimers” or “arborols” 
[98-100]. 
Dendrimers consist of a central core molecule which acts as the root from which a 
number of highly branched, tree-like arms originate in an ordered and symmetric 
fashion  [101, 102] as can been seen in Fig2.3. Their unique molecular architecture 
means that dendrimers have a number of distinctive properties which differentiate 
them from other polymers. Firstly, the gradual stepwise method of synthesis means 
that they have in general a well defined size and structure with a comparatively low 
polydispersity index [102]. Furthermore, dendrimer chemistry is quite adaptable thus 
facilitating synthesis of a broad range of molecules with different functionality. Key 
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properties in terms of the potential use of these materials in drug and gene delivery 
are defined by the high density of terminal groups.  
 
Fig.2.3. [103] Dendrimer well defined hierarchical structure. 
 
PAMAM and PPI dendrimers are two most popular commercially available 
dendrimers and PAMAM dendrimers are the first exploration of dendrimers as 
molecules for gene delivery. [104] PAMAM dendrimers are normally based on an 
ethylenediamine or ammonia core with four and three branching points. The molecule 
is built up iteratively from the core through addition of methyllacrylate followed by 
amidation of the resulting ester with ethylenediamine, which is usually called a 
divergent approach. Each complete sequence generated by the divergent reaction 
results in a new full dendrimer generation, such as G1, G2… with the terminal amine 
terminate the reaction in anionic carboxylate groups and it is usually called as half 
generations, such as G3.5, G4.5 etc [103]. The other commercially available PPI 
dendrimer is based on polypropylenimine (PPI) units with butylenediamine (DAB) 
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used as the core molecule. The repetitive reaction sequence involves Michael addition 
of acrylonitrile to a primary amino group followed by hydrogenation of nitrile groups 
to primary amino groups [105]. These dendrimers are frequently referred to as DAB-x, 
or DAB-Am-x, with x giving the number of surface amines [103]. Dendrimer shape 
changes with generation [106, 107]. The lower generations acquire a more open 
planar–elliptical shape while a more compact spherical shape for higher generations 
which causes the intrinsic viscosity of dendrimer solutions does not increase linearly 
with mass but shows a maximum at a specific generation and the compact shape also 
reduces the likelihood of entanglement which affects larger classical polymers. 
The biological cytotoxicity must be evaluated when they were applied in the 
biological experiment acting as the drug and gene delivery system. In the cytotoxicity 
assay, PAMAM dendrimer showed comparably lower toxicity than some of the other 
transfection agents, in particular cationic polymers of higher molecular weight such as 
PEI (600–1000kDa), PLL (36.6kDa), or DEAE–dextran (500kDa) [108]. Cytotoxicity 
of PAMAM dendrimers increases with generation [109], independent of surface 
charge, however PPI dendrimers with DAB and DAE cores did not show generation 
dependence for the cytotoxicity. 
Small dendrimer DNA complexes with a ratio of significant excess of positive to 
negative charge (6:1) were most efficient but strongly affected by the presence of 
serum [110] which is similar with the property of other cationic polymers such as PEI. 
In contrast to poly-l-lysine, dendrimers transfection process was not dependent on the 
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presence of lysosomotropic agents, suggesting that they had an intrinsic ability to 
escape from the endosome. The authors suggested that this ability may be related to 
the ability of the dendrimer amine groups to buffer pH changes in the endosome [110, 
111]. PAMAM dendrimers with the generation G3 to G10 were found to form stable 
complexes with DNA their ability to transfect different cell lines varies. Overall the 
higher generation dendrimers (G5–G10) were found to be of superior efficiency 
[103]. 
In a comparative evaluation of various polyplexes based on linear, branched, and 
dendritic polymer structures, Gebhart and colleagues demonstrated that the 
transfection activity between these polymers varied by 3 orders of magnitude [103, 
112] and they also ranked the best transfection agents according to their ability to 
transfect a panel of cell lines. The ranking was 22 kDa linear PEI (ExGen 500™) > 
activated PAMAM dendrimer (Superfect™) 25 kDa branched PEI > P123-g-PEI(2 k), 
a Pluronic PEI graft block copolymer. These polymer based systems were found to be 
more active than some of the commercial cationic lipid systems [112]. However, 
transfection activity varied up to 3 orders of magnitude depending on the specific cell 
line. Interestingly the same study also demonstrated that other factors such as 
incubation time of the complexes with the cells, or cell density will affect different 
polymers to a varying degree, that is, linear PEI 22 kDa based complexes show a cell 
density dependence, while the fractionated PAMAM dendrimer complexes 
(Superfect™) show some time dependence, requiring longer incubation time[112]. 
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A PPI dendrimer with DAB core (DAB-Am64, Astramol™), despite the similar 
architecture to the PAMAM dendrimer, appeared to be the least efficient agent. Its 
application was also hampered by signs of toxicity at higher N/P ratios [113], which 
had been highlighted previously [114]. DAB-PPI dendrimers–as for most other 
synthetic transfection agents–a balance needs to be struck between the ability to 
facilitate transfection and cytotoxicity [114]. Both the ability of DAB-PPI dendrimers 
to bind DNA, as well as their cytotoxicity, is generation dependent.  
2.4.3 Chitosan 
Chitosan [a (1→4) 2-amino-2-deoxy-β- -glucan] [115], a natural polymer obtained 
by the alkaline deacetylation of chitin, is non-toxic, biocompatible, and biodegradable 
that forms poly-electrolyte complexes with DNA. Chitin is the second most abundant 
polysaccharides in nature, cellulose being the most abundant. Chitosans [116], a 
family of linear binary polysaccharides consisting of (1 f 4)-â-linked 
2-acetamido-2-deoxy- Dglucose(GlcNAc) and its de-N-acetylated analogue (GlcN), 
have emerged as a biocompatible alternative to synthetic polycations, suitable for in 
vivo gene delivery to mucosal tissues.[117-119]. Besides biodegradability, and low 
toxicity,[116, 117] chitosan also offers an advantage inherent to synthetic PC; its 
properties may be tuned through the fraction of acetylated units (FA), degree of 
polymerization (DP), and its polydispersity, as well as the pH-dependent degree of 
ionization. Tailoring of chitosans with respect to FA, DP, and polydispersity provides 
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a tool for controlling the functional properties of chitosan. Chitosans differ in degree 
of N-acetylation (40–98%) and molecular weight (50–2000kDa) [115].  
Mucoadhesive property of chitosan potentially permits a sustained interaction of the 
macromolecule to be ‘delivered’ with the membrane epithelia, promoting more 
efficient uptake [79]. Chitosan excels in enhancing the transport of drugs across the 
cell membrane. Its cationic polyelectrolyte nature provides a strong electrostatic 
interaction with mucus, negatively charged mucosal surfaces and other 
macromolecules such as DNA. In all, due to its non-toxic property and good 
biocompatible ability, chitosan is widely used in the pharmaceutical research as a 
carrier for drug and gene delivery system. 
The chitosan backbone of glucosamine units shows a high density of amino groups, 
and requires pH values below 6 to be soluble [120]. In acidic mediums, the amine 
groups will be positively charged, conferring to the polysaccharide a high charge 
density [80]. At physiological pH, not all of the amino groups [120] are protonated. 
Chitosan /DNA ratios in complexes are therefore better expressed as N/P ratios as the 
number of polymer nitrogen (N) per DNA phosphate (P). 
The size of the complexes is of crucial importance to cellular uptake. The smaller size 
complexes have the advantage of entering the cells through endocytosis and/or 
pinocytosis, therefore increasing the transfection rate. Although the cationic polymer 
can self assembly form complexes with plasmid DNA, the specific preparation 
procedures and details such as the N/P ratio [121-123] between chitosan and DNA, 
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the buffer solution and even the temperature [124] might affect the particle size, 
therefore the transfection efficiency. The most popular method to prepare small 
plasmid/chitosan nanoparticles (200–300 nm) were prepared by complex coacervation 
method [119, 124, 125]. Generally [124], chitosan solution in sodium acetate buffer, 
pH 5.5 and DNA solution of 100 μg/ml in sodium sulfate solution were preheated to 
50–55°C separately. Then the solutions were quickly mixed together and vortexed for 
15–30 s according to the specific N/P ratio. To yield uniform nanoparticles, the final 
volume of the mixture in each preparation was limited to below 500 μl in order. The 
chitosan-DNA nanoparticles formed as a result of complex coacervation between 
chitosan and DNA and the nature of the interaction involved in the nanoparticle 
formation is predominantly electrostatic. The first step of chitosan-DNA nanoparticle 
preparation was the complex formation between the two oppositely charged 
polyelectrolytes, chitosan and DNA. Under defined conditions, phase separation 
occurred to yield coacervates that represented the aggregated colloidal complexes 
[124]. Sodium sulfate was included as a dissolving reagent to facilitate the phase 
separation, since with a greater affinity for water it facilitates the removal of the 
associated water layer from around the dissolved colloidal chains. The pH of the 
buffer at 5–5.8 and a temperature of the solution above 50°C resulted in 
chitosan-DNA nanoparticles with the least aggregation [124]. 
The transfection efficacy seen in vitro is also cell type-dependent [122, 126, 127]. 
Moreover, effect of the molecular weight of chitosan [128, 129], and the degree of 
chitosan deacetylation [122, 129] can also influence the efficiency of gene 
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transfection. Chitosan vectors of higher molecular weight and degree of deacetylation 
were more efficient at retaining the DNA upon dilution, and consequentially, more 
capable of protecting the condensed DNA from degradation by DNase and serum 
components. The cellular uptake was also affected by this factor that chitosan vector 
with lower molecular weight or lower degree of deacetylation shows showed lower 
Zeta potential. These factors contributed to the low transfection efficiencies for 
chitosan vectors of low molecular weight or degree of deacetylation [129]. 
Although as a cationic polymer, chitosan and its derivatives was shown to be a 
suitable material for efficient non-viral gene and DNA vaccine delivery, the 
transfection efficiency and transfection rate still need to be improved comparing to the 
viral vectors and cationic lipids. Many strategies have been developed to improve this 
promising polymer. For example, people modified chitosan in gene therapy according 
to different cell lines by conjugating specific targeting receptor groups such as the 
galactosylated chitosan-graft-polyethylenglycol which is specific for the HepG2 cell 
lines [130].    
Another unique advantage of chitosan in drug and gene delivery is its mucoadhesive 
properties and also for the apparent ability to enhance penetration across the nasal 
mucosa [131]. Due to this property, the delivery system utilizing chitosan for the 
formulation of micro or nanoparticles has been investigated by many researchers for 
developing nasal and pulmonary gene and DNA vaccine delivery systems. We will 
discuss the application of chitosan with nanoparticles separately. 
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2.4.4 Polyethylenimine (PEI) 
 
Polyethylenimine is a polymer that has been known for quite a long time and which 
has been widely used in processes such as paper production, water purification, and 
shampoo manufacturing [132]. Since the first published examination of poly 
(ethylenimine) (PEI) as a gene delivery vehicle, there has been a flurry of research 
aimed at this polycation and its role in gene therapy. PEI has become one of the most 
popular reagents for transfection of cells in culture and has been found to be one of 
the most efficacious non-viral agents[133, 134], on a fast-growing market that is 
boosted by human and animal genome sequencing.   
 
       
 
Fig.2.4  Structure of Linear and Branched PEI [132] 
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PEIs exist in a linear and branched topology and are commercially available in a wide 
range of molecular weights (e.g., 700 Da, 2, 25, 50, 70, 800 kDa). The branched form 
is produced by acid catalyzed [135] polymerization of aziridine monomers, resulting 
in random branched polymers, while linear forms of PEI are attainable by a similar 
process, but performed at lower temperature [132] [136]. The structure of these two 
forms of PEI can be seen in Fig 2.4. The ethylene amine repeating unit bestows to 
these polymers high water solubility [135]. Another most important feature of these 
molecules is their high cationic charge density, since every third atom is a potentially 
protonable amino nitrogen and this feature is one of the reasons that PEI is the most 
potent cationic polymer for gene delivery. According to the protonation versus pH 
profile of free PEI, every fifth or sixth amino nitrogen is protonated at physiological 
pH [135, 137]. Binding of nucleic acid to PEI will slightly shift the protonation profile 
of PEI, but still only every second to the third nitrogen will be protonated at 
physiological pH. For example, the branched polycation containing primary, 
secondary, and tertiary amino groups in a 1:2:1 ratio. These amines have pKa values 
spanning the physiological pH range, resulting in buffer capacity [138].  Therefore, 
in contrast to polymers such as polylysine (PLL) and chitosan, PEI has a 
comparatively higher buffer capacity over a very broad pH range [134, 135]. 
 
Numerous researchers tend to work to elucidate the mechanism of PEI mediated gene 
transfer and the most popular one which is accepted by most people now is the proton 
sponge hypothesis [138, 139]. The proton sponge nature of PEI is thought to lead to 
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ions to maintain charge neutrality, increase ionic strength inside the endosome, which 
is then thought to cause osmotic swelling and physical rupture of the endosome, 
resulting in the escape of the vector from the degradative lysosomal trafficking 
pathway [138].  
 
Recent years, the branched PEI-derived vectors have been used to deliver 
oligonucleotides, plasmid DNA (pDNA), as well as RNA and intact ribozymes. The 
efficacy of branched PEI-derived vectors non-viral vectors and their cytotoxic effects 
depend to a remarkable extent on material characteristics like the molecular weight, 
the degree of branching, the cationic charge density and buffer capacity, polyplex 
properties, such as the DNA content, particle size and zeta potential and the 
experimental conditions like the polyplex concentration, the presence or absence of 
serum during transfection, the incubation time and the transfection model chosen for 
the gene delivery experiment [140].  
 
Compared to lower molecular weight derivatives, high molecular weight branched 
PEI up to 800kDa has been used for non-viral gene transfer, exhibiting a superior 
capability to form compact and stable PEI/DNA complexes and increased transfection 
efficiency [141]. However, the increased cytotoxicity always comes with the high 
transfection ability of the high molecular weight of PEI. Thus the low molecular 
weight of PEI which is less toxic to the cells has been adopted (5–48kDa)[140, 142, 
143], but the amplified polymer concentrations are needed to achieve comparable 
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efficacy. Due to their reduced cytotoxicity, the high N/P ratios were tolerated and 
added to the superior performance in vitro, irrespective of the absence or presence of 
serum. Generally speaking, the N/P ratio, and with it the zeta potential, dramatically 
influences the efficacy of the gene delivery system. At high N/P ratios, the positive net 
charge of the corresponding complexes increases, improving cell interaction and 
enhancing the cellular and nuclear uptake and retention [140, 144]. The cytotoxic 
effects correlate with the molecular weight of the polymer and intra-nuclear polymer 
concentration [145] and increase with a prolonged incubation period. 
 
Besides the molecular weight of PEI and the zeta potential, the particle size and the 
shape of the PEI/DNA complex also plays an important role in determining the 
transfection efficiency especially for the in vivo experiment, such as circulation 
through the blood, passage through the various biological barriers, and diffusion 
through tissues. Particle size [135] will also be important for uptake and removal by 
cells of the reticuloendothelial (RES) system, particularly in the liver and spleen. The 
most important factor to affect the particle size might be the N/P ratio. The optimized 
N/P ratio needs to be found for different molecular weight PEI to achieve the 
maximum transfection efficiency. Higher N/P ratios often lead to small complex but 
increased cytotoxicity. Besides being a function of the polycation-to-DNA ratio, the 
size and shape of the polycation /DNA complexes are also dependent on the 
experimental protocol of complex formation with parameters such as the ionic 
strength of the solvent, the kinetics of mixing, the DNA concentration, and the 
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sequence of addition of polycation or DNA having pronounced effects [135]. In 
Boussif and his colleagues [139, 146] work, they first stressed the importance of the 
order of addition of the reagents, with drop wise addition of the polymer to the 
plasmid producing polyplexes with 10-fold higher transfection efficacy in vitro 
compared to those obtained by adding the DNA to the polymer. Some other factors 
that may influence the formation of the complex include the concentration of the 
DNA and polymer solution, the ratios between the DNA and polymer solution and the 
mixing speed.  When the complex formed at low salt concentrations (5% glucose), 
PEI/DNA complex were found to form toroid structures of 40–60 nm [147] to 50–80 
nm [148] (as estimated by dynamic laser light scattering), or even 20–40 nm [149] (as 
estimated using atomic force microscopy). This phenomenon is consistent between 
complexes made with different PEIs, including the linear and branched PEIs. 
However when formed at higher ionic concentration, the PEI/DNA complex might 
aggregate, and the particle size might increase to 100nm, especially when the salt 
concentration reached to the physiological concentration, large aggregation of 
PEI/DNA complex would appear. And the aggregation behavior is different for 
different types of PEIs. Compared to the rather stably condensed DNA complexes 
formed with branched PEIs, complexes with linear PEI seem have lower stability, 
which allows the initially small complexes, when formed at low ionic strength, grow 
as soon as they are transferred into a medium of physiological ionic strength. This 
growth were observed in vitro, based on this point, people speculate that this 
phenomena might one of the mechanisms underlying the exceptionally high 
 38
transfection efficacy found in the lungs with linear PEI complexes [150]. 
 
Most non-viral DNA carriers have their optimal transfection activity when the 
particles present an overall net positive charge so that the cationic charges allow 
binding of the complexes to anionic proteoglycans that are present on the cell surface. 
However, the excessive positive charge of the polymer/DNA complex poses major 
problems when DNA complexes are introduced into the blood circulation. Indeed, 
positively charged complexes not only induce erythrocyte aggregation [151, 152], but 
can also interact with plasma components such as albumin, fibrinogen and 
complement C3 [151]. As a result, these positively charged complexes are cleared 
from the circulation within minutes after tail vein injection and most of the complexes 
would accumulate in the lung, then in the liver [153-156] for the non-specific 
transfection assay in vivo. Taken things together, despite considerable transfectional 
activity, the properties of PEIs need to be further improved. Therefore, various 
modifications of PEIs have been explored in recent years. Strategies developed to 
shield the positive charge and achieve the targeting ability to the specific organs 
included by increasing the in vivo half-life of the complexes or by using cell specific 
ligands [157, 158]. These non-specific interactions can be blocked by shielding the 
surface by PEGylation, which avoided the activation of the cascade components in the 
interaction. This covalent modification of PEI increase the blood circulation time of 
the complexes not only because it reduced the positive surface charge of the 
polyplexes, but also because PEG acting as the hydrophilic arms also reduce the 
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non-specific ionic interactions between polyplexes and target cells [159]. Although 
the in vitro transfection efficiency of PEG-PEI conjugates is significantly lower than 
that of the corresponding non-modified polymer, Shielding of PEI/DNA complexes in 
this manner reduces their interaction with erythrocytes and increased circulation times 
before being cleared from the blood stream as compared to unshielded complexes 
[152]. Another beneficial effect of PEGylation that was observed is that the PEG-PEI 
conjugates are less cytotoxic than the non-modified polymers. This, however, may be 
related to the fact that less PEG-PEI/DNA complexes are taken up by the cells (see 
above). It was also found that PEG chains dramatically increase the solubility of the 
DNA complexes due to its hydrophilic property. Other compounds used as the 
shielding regents are poly-N-(2-hydroxy-propyl) methacrylamide (pHPMA) and 
poloxamer. For example, local application of DNA shielded with poloxamers 
increased gene expression in muscle and appeared diffuse throughout the tissue more 
efficiently [160].  
 
In all, the main disadvantage of PEGylation is that it reduces the DNA-binding 
capacity of the polymer and it hinders interactions of the polyplexes with the target 
cells. Therefore, to increase its usefulness, the stealth strategy needs to be improved 
by combining with the use of ligands that allow specific cell targeting. People also 
found direct shielding with the ligand such as transferrin covalently attaching to the 
polycation would also cause the decrease of the zeta potential of the polyplexes. The 
toxicity of the complexes was future reduced when applied in vivo[161]. Table 2.1 
 40
lists the current ligands used for the targeting of the DNA complexes. The ligands 
used might be sugar residues, peptides, proteins and antibodies.  
 
Table 2.1 Ligands used to target PEI/DNA complexes [162] 



































PECAM Endothelial cells 
 
 
Currently three chemical strategies have been adopted for the formation of PEGylated 
ligand-containing PEI/DNA complexes as demonstrated in Fig2.5. The first method is 
as shown in Fig 2. 5 A, the ligand reacts with the functionalized distal end of the 
hydrophilic arm after PEGylation of PEI. The last step then consists of condensing the 
DNA with the ligand-PEG-PEI conjugate. This strategy was used, for example, by 
two different groups for the synthesis of galactose-PEG-PEI conjugates [163, 
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164].The second method in Fig2.5B shows that PEI/DNA complexes are first 
generated and then the resulting polyplexes are modified by a heterobifunctional PEG 
which reacts with amino groups of PEI.  Ligands are finally incorporated into the 
complexes by conjugation with the distal end of the PEG. The preparation of 
EGF-PEG-PEI/DNA complexes used this strategy [165]. The last strategy in Fig 2.5 
C involves: the first step consists of covalently coupling the ligand to PEI. Addition of 
plasmid DNA leads to the formation of ligand-PEI/DNA complexes which are 
subsequently modified with PEG chains. In this case, PEG may not only mask the 
positive charges of the polyplexes, but also shield the ligand bound to the polymer, 
thereby preventing the recognition of the ligand by the target cell. By using this 
method, PEGylation of transferrin-PEI 800 kDa/DNA complexes strongly reduces 
plasma protein binding and erythrocyte aggregation [151, 159]. 
 
Results from the last decade show that gene transfer with cationic polymers such as 
PEIs has considerable success. However, in order to reach the transfection efficiencies 


















Fig.2.5 Strategies for the PEGylation of PEI/DNA polyplexes: (A) a ligand–PEI 
conjugate is used to complex pDNA and the corresponding polyplex is pegylated in a 
second step. (B) PEI is used to condense pDNA. In a second step, PEG is conjugated 
to the polyplex surface. Finally, the ligand is attached to the distal ends of the PEG 
chains. (C) A mixture of ligand-decorated PEG–PEI copolymer, PEG–PEI copolymer 
and the homopolymer PEI is used to complex DNA, leading to the formation of 
PEG-shielded, ligand-decorated PEI/DNA polyplexes in a one step procedure. 
(Reprinted from Ogris’s review)[166]. 
 
2.5 PLA and PLGA based biodegradable nanoparticles 
 
Biodegradable colloidal particles have received considerable attention as a possible 
means of delivering drugs and genes by several routes of administration because they 
have advantages such as high stability, easy uptake into the cells by endocytosis, and 
the targeting ability to specific tissues or organs by adsorption or coating with ligand 
materials at the surface of the particles [165]. Special interest has been focused on the 
use of particles prepared from polyesters poly(lactic acid) (PLA) and 
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poly(D,L-lactide-co-glycolide) (PLGA) polymers, which are biocompatible and 
biodegradable and have been approved by the FDA for certain human clinical uses 
[167], due to their biocompatibility through natural pathways [168, 169]. As 
polyesters in nature, these polymers undergo hydrolysis upon implantation into the 
body, forming biologically compatible and metabolizable moieties (lactic acid and 
glycolic acid) that are eventually removed from the body by the citric acid cycle. 
Polymer biodegradation products are formed at a very slow rate, and hence they do 
not affect the normal cell function [170]. Biodegradable nanoparticle system has 
many advantages [170] in gene delivery due to their biodegradability submicron size. 
In general, these systems can be chemically modified to provide targeted 
(cellular/tissue) delivery of drugs, to improve oral bioavailability, to sustain drug/gene 
effect in target tissue, to solubilize drugs for intravascular delivery, and to improve 
the stability of therapeutic agents against enzymatic degradation (nucleases and 
proteases), especially of protein, peptide, and nucleic acids drugs. The nanometer 
size-ranges of these delivery systems offer certain distinct advantages for drug 
delivery. Due to their sub-cellular and sub-micron size, nanoparticles can penetrate 
deep into tissues through fine capillaries, cross the fenestration present in the 
epithelial lining (e.g., liver), and are generally taken up efficiently by the cells [171]. 
This allows efficient delivery of therapeutic agents to target sites in the body. Also, by 
modulating polymer characteristics, one can control the release of a therapeutic agent 
from nanoparticles to achieve desired therapeutic level in target tissue for required 
duration for optimal therapeutic efficacy. Further, nanoparticles can be delivered to 
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distant target sites either by localized delivery using a catheter-based approach with a 
minimal invasive procedure [172] or they can be conjugated to a biospecific ligand 
which could direct them to the target tissue or organ [173, 174]. 
 
PLGA is synthetic polyester composed of one or more of three different hydroxy acid 
monomers, D-lactic, L-lactic, and/or glycolic acids. Generally as a kind of synthetic 
polymer, it can be made to highly crystalline [e.g., poly (L-lactic acid)], or completely 
amorphous [e.g., poly(D,L-lactic- co-glycolic acid) by adjusting the ratio of the 
monomers, can be processed into most any shape and size (down to <200 nm), and 
can encapsulate molecules of virtually any size [175]. The degradation time of PLGA 
can be altered from days to years by changing the polymer molecular weight, the 
lactic acid to glycolic acid ratio in copolymer, or the structure of PLGA nanoparticles.  
 
One reason that biodegradable nanoparticles have been suggested to be good gene 
delivery carriers is the possibility of achieving a safe and sustained release property. 
Various PLGA based sustained release systems for gene delivery has been developed 
in these recent years [176-179]. These nanoparticle systems carrying DNA may fall 
into two groups, one is DNA entrapment system and the other is the DNA surface 
binding system. DNA entrapment system is the common nanoparticle system, which 
encapsulates the pDNA. This system has the advantages of pDNA protection along 
with the controlled release. PLGA nanoparticles are generally formulated using 
emulsion solvent evaporation (double emulsion technique) or by solvent displacement 
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techniques [180]. Polyvinyl alcohol (PVA) has been the most commonly used 
emulsifier for the formulation of PLGA nanoparticles because the particles formed 
using this emulsifier are relatively uniform and smaller in size, and are easy to 
redisperse in aqueous medium. However, PVA on the surface of the nanoparticles was 
demonstrated to slightly inhibit cellular uptake of the nanoparticles [167]. The main 
disadvantage of the DNA entrapment system is its low loading efficiency of DNA 
because of the hydrophobic and the anionic property of this polyester. People tried to 
introduce some cationic polymers such as PEI to improve this system, where they 
utilized the PLGA nanoparticles to encapsulate the PEI/DNA complex [181]. Surface 
binding systems [22, 182] utilize the ionic interaction between the cationic polymers 
and the anionic pDNA. In this case, DNA was bound on the surface of the cationic 
nanoparticles and chitosan and PEI were the mostly used cationic polymers.  Fig2. 6 
schematically show the different mechanisms of different DNA delivery system of 




Fig.2.6 Strategies for assembling nanoparticles (a. b) In traditional strategies, DNA is 
condensed with polyamines, polycationic lipids or neutral polymers to generate DNA 
nanoparticles with radii of 20-100nm (a) or DNA is coated onto a solid as a silica 
nanoparticles (b). (c) Alternatively, the DNA can be electroporated into hollow 
yeast-derived nanoparticles incorporating viral envelope glycoproteins that can be 





Non-viral gene therapy has significant clinical potential, yet its therapeutic utility has 
been hindered by low transfection efficiency and modifications of these systems still 
need to be developed to overcome the multiple barriers for the delivery system. The 
desirable properties of non-viral gene delivery systems should include 
biocompatibility (low toxicity, non-immunogenicity and in vivo stability), efficient 
nucleic acid delivery with high functionality, and manufacture in a commercially 
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acceptable form amenable to scale-up and storage stability. Although the perfect 
system does not currently exist, recent studies on each of the aforementioned issues 





















Chapter 3 Materials and Methods 
3.1 Nanoparticles for RNAi delivery 
3.1.1 Materials  
Poly(D, L-lactide-co-glycolide) (PLGA), of a lactide-glycolide ratio of 50:50, HMW 
Polyethyleneimine (PEI 25 kd, branched, water-free) and LMW PEI (800, branched, 
water-free) were all purchased from Sigma. Chitosan (extracted from crab shells, 
minimum of 85% deacetylated), supplied from Sigma, was purified by re precipitation 
from the filtered 1% acetic acid solution with sodium hydroxide before use. The 
precipitate was washed with deionized water and dried under vacuum. The purified 
chitosan was dissolved in 1% acetic acid using magnetic stir and gently heating and 
PH was adjusted to 5.5-5.7 with sodium hydroxide. The solution was diluted to 0.02% 
of chitosan (w/v) and then sterile filtered through a 0.22 μm filter before use. 
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) was synthesized by the 
ring opening polymerization according to previous study of others[184].  
 
The double strand RNA (dsRNA) used was chemically synthesized by 
Qiagen-Xeragon (QIAGEN GmbH, German).Sequences of two types of SiRNA used 
in this experiment was according to Li et al[185]. S1SiRNA targets sites within the 
HBsAg ORF of the viral genome which are conserved in all the different HBV 
serotypes while ScrSiRNA served as the scramble control with some random 
sequence. The sequence is as follows:   
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S1 SiRNA  
  5’-GGUAUGUUGCCCGUUUGUCdTdT-3’ 
3’-dTdTCCAUACAACGGGCAAACAG-5’ 
Scr SiRNA 
    5’-CUCAACCUACCAACUCCACdTdT-3’ 
3’-dTdTGAGUUGGAUGGUUGAGGUG-5’ 
 
3.1.2. Cell culture 
 
The PLC/PRF/5 and the 2.2.15 human liver cell lines were maintained in  
Dulbeccco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine 
serum, 2mM L-glutamine, 1mM sodium pyruvate, 0.1mM MEM nonessential amino 
acids, 100U/ml penicillin and 100μg at 37 oC in a humidified atmosphere containing 
5% CO2.   
 
3.1.3 Nanoparticle Preparation  
Cationic MPEG-PLA nanoparticles were prepared by the nanoprecipitation method 
[186]. The organic phase prepared by dissolving 100mg MPEG-PLA in 10ml 
acetronitrile was drop-wise added to 50ml 100mg/ml PEI25kd solution (filtered 
through 0.22μm membrane filter). The whole mixture was then evaporated with a 
magnetic stir overnight to remove the organic solvent. The obtained suspension was 
then centrifuged for 15mins at 4 oC and at 12,000rpm (Eppendorf 5810R) in order to 
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remove the excessive surfactant. The pellet was then suspended and slightly sonicated 
to form the evenly distributed nanoparticle suspension at the final concentration of 
10mg/ml.   
 
Cationic PLGA nanoparticles were prepared using solvent evaporation technique. 
Briefly, 100mg PLGA polymer was first dissolved in 10ml Dichloromethane (DCM) 
to form the oil phase. The water phase was formed by the mixture of chitosan solution 
and PVA solution at the final concentration of 2mg/ml of chitosan and 66.7mg/ml of 
PVA. The oil phase was then mixed with the water phase and the whole mixture was 
sonicated at 25w for 2 minutes. The milk-like emulsion was then evaporated with a 
magnetic stir overnight to remove the organic solvent. The obtained suspension was 
then centrifuged for 15mins at 4 oC and at 12,000rpm (Eppendorf 5810R) in order to 
remove the excessive surfactant. The pellet was then suspended and slightly sonicated 
to form the evenly distributed nanoparticle suspension at the final concentration of 
10mg/ml.   
 
 
3.1.4. Characterization of nanoparticles 
3.1.4.1 Size and Size distribution 
Size and size distribution property of nanoparticle plays a key role in determining its 
internalization behavior. The particle size and size distribution of the cationic 
nanoparticles were measured by the laser light scattering method (Brookhaven 
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Instruments Corporation 90 plus Particle Size) at 25 oC and at a scattering angle of 90o. 
Nanoparticle after centrifugation was diluted with deionized water and slightly 
sonicated to obtain homologous suspension before measurement. Then the suspension 
was used to measure the mean diameter, size distribution and polydispersity. 
 
3.1.4.2 Surface Morphology 
The formulated nanoparticles was investigated by observing the freeze-dried particles 
using Field Emission Scanning Electron Microscopy, (FESEM, Jeol JSM 5600LV), 
which requires an ion coating with platinum by a sputter coater (JFC- 1300, Jeol, 
Tokyo) for 40 s in a vacuum at a current intensity of 40mA after preparing the sample 
on metallic studs with double-sided conductive tape. AFM (Multimode Scanning 
Probe Microscope, Digital Instruments) was used to study the surface morphology 
with Nanoscope IIIa controller using the tapping mode. Before observation, the 
particles were fixed on a double-sided sticky tape, which was adhered to a sample 
stand. 
 
3.1.4.3 Surface charge measurement 
Zeta potential measured by the laser Doppler anemometry (Zeta Plus, Zeta Potential 
Analyzer, Brookhaven Instruments Corporation) was employed to evaluate surface 
charge density of the nanoparticles. Sample was prepared as the method mentioned in 
the size and size distribution part.  
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3.1.4.4. X-ray photoelectron spectroscopy (XPS) 
The XPS (AXIS His-165 Ultra, Kratos Analytical, Shimadzu) was used to analyze the 
surface composition of the nanoparticles. Fixed transmission mode was utilized with 
pass energy of 80 eV for the survey spectrum covering a binding energy from 0 to 
1200 eV. Peak curve fitting was carried out using the software provided by the 
instrument manufacturer.  
 
3.1.5 Gel retardation assay 
The potential of these nanoparticles as gene carrier was further studied to perform the 
gel retardation assay. Nanoparticle (PLGA/PEI) suspensions with the concentration of 
10mg/ml were added into the RNA suspension at a concentration of 0.3mg/ml at 
different ratios with range from 1:1 to 30:1 (w:w in RNA suspension buffer) and then 
vortexed for 30 seconds. After incubation at room temperature for 30 minutes, 
nanoparticle-RNA complex was formed. The nanoparticle-RNA complexes were 
electrophored on the 1% agarose gel containing 0.6% ethidium bromide for 30 min at 
100mv. Images were acquired using Gel Doc 1000 Video Gel Documentation System 
(Bio-Rad Laboratories, Inc., Hercules, and CA). ). All the other three types of 
nanoparticles were then further studied for their carrier capacity.   
 
3.1.6 Nanoparticles mediated transfection with siRNAs  
PLC/PRF/5 cells were seeded into 24-well plate (COS, USA) at a density of 5*104 
cells per well and allowed to recover for 24 hours before transfection. After overnight 
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incubation, culture medium in each well was replaced with 300μl Opti-MEM I 
Reduced Serum Medium. The complex of nanoparticle and RNAi in suspension were 
added into each well and mixed gently. Transfection happened when the cells with the 
complex were incubated at 37oC 5% CO2. After incubation for four hours, transfection 
reagent in each well was removed and replaced with fresh medium.      
 
3.1.7 Cell Viability Assay 
PLC/PRF/5 cells were plated at a density of 5*103 per well in 96-well microtiter 
plates (NUNC, Germany). After overnight incubation, culture medium was replaced 
with fresh medium containing nanoparticles with the concentration of 200μg/ml 
which is similar with the concentration used in the transfection experiments. Cell with 
these supplements were then incubated for 48 hours. For cell viability assay, 20μl 
MTS tetrazolium compound reaction solution [3-(4, 5-dimethylthiazol-2-yl) - 
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and 4.8 μl Phenazine 
methosulfate (PMS)) was directly added to each sample.  Samples were incubated 
with the reagent for one hour in the CO2 incubator at 37 °C. Absorbance was 
measured at 492 nm using Genios Micro plate reader (Tecan, Mannedorf, Australia). 
Quintuplicate determinations for each treatment were performed. The relative cell 
viability of sample related to control cells supplemented only with fresh medium was 
indicted by calculating the ratio of two absorbance values. 
 
3.2. TPGS enhancement for gene transfection efficiency 
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3.2.1 Materials 
Branched polyethylenimine (PEI, MW 25,000) was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate 
(Vitamin E TPGS or simply TPGS) was obtained from Eastman (TN, USA). 
P-CMV-β-GAL plasmid DNA was obtained from Invitrogen Corporation.  High 
Sensitivity ß-Galactosidase Assay Kit and β-gal assay kit was from STRATAGENE. 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H- 
tetrazolium, (MTS) reagent (supplied as Cell Tilter 96 Aqueous One Solution Cell 
Proliferation Assay) was purchased from Promega (Madison, WI, USA). Phosphate 
buffered saline (PBS), MEM medium, penicillin-streptomycin solution, 
Trypsin-EDTA solution, Tritons X-100 and Hank’s balanced salt solution (HBSS) 
were purchased from Sigma (St. Louis,MO, USA). Fluorescent polystyrene 
nanoparticles were purchased from Duke Scientific (CA, USA). Fetal bovine serum 
(FBS) was received from Gibco (Life Technologies, AG) 
Commercially available plasmid DNA of Plasmid pCMV·SPORT-bgal (Invitrogen) 
encoding the reporter gene of b-galactosidase (b-gal) was used in this study. This 
plasmid carries the cytomegalovirus (CMV) promoter and enhancer that drive the 
b-gal gene. The pCMV-b-gal plasmid was amplified in transformed DH5x-T1 
Competen E.coli cells ( Invitrogen) in 5 ml of Luria Bertani agar broth supplemented 
with 50 íg/mL ampicillin (Sigma) at 37 °C. The mixture was gently shaken overnight 
at 225 rpm. The amplified plasmid DNA was purified using Hispeed Maxi kit (Qiagen) 
The concentration of pDNA was then measured by ultraviolet absorbance with a 
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Genios Micro plate reader at 260 nm (Tecan, Mannedorf, Australia). The purity of the 
pDNA was confirmed by 0.8% agarose gel electrophoresis. 
 
3.2.2 Cell culture 
The Madin-Darby Canine Kidney (MDCK) type I cell line was obtained from K. 
Prydz (Oslo) and cultured in DMEM, supplemented with 10% fetal bovine serum, 
100u/ml penicillin, 100μg/ml streptomycin, 2mM glutamine, 1mM sodium pyruvate 
and 0.1mM MEM nonessential amino acids. 
 
The NIH3T3 Swiss mouse embryo cell line was obtained from American Type 
Culture Collection (ATCC, Rockville, MD) and was grown in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10％ fetal bovine serum( Hyclone lab, 
Logan, UT), and 1% penicillin-streptomycin solution.  
 
The Caco-2 cells (ATCC, VA, USA) of passages between 24 and 30 were used. 
Caco-2 cells were cultured in MEM medium with 1.5mM L-glutamine, supplemented 
with 20% FBS, 1mM sodium pyruvate, 1.5 g/L of sodium bicarbonate and 1% 
penicillin-streptomycin solution. All cells were seeded at 5*104 cells/well on the 
24-well plates with transparent bottom (Costar, IL, USA) for transfection experiments 
and seeded at 1*104 cells/well on the 96-well plates with transparent bottom (Costar, 
IL, USA) for cell viability assay. All cells were cultured as a monolayer at 37 oC in a 
humidified atmosphere containing 5% CO2. All the cell culture reagents including 
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Opti-MEM Reduced Serum Medium were purchased from Gibco BRL (Grand Island, 
NY, USA). 
 
3.2.3 Preparation of DNA/ PEI25kd complexes 
The PEI/DNA complex was prepared as follows. Briefly, plasmid DNA was first 
diluted by 5% glucose to the concentration of 0.5ug/ml. Titrated PEI 25kd solution 
was diluted to 10nmol and filtered with 0.22μm (Millipore) syringe filter for 
sterilization. The required PEI amount, according to DNA concentration was 
calculated by taking into account that 1μg DNA contains 3nmol of phosphate and 
0.1M PEI contains 0.1M amine nitrogen. Herein, we use N (nitrogen)/P (Phosphate) 
ratio to describe the molar ration of PEI and DNA.  Certain amount of PEI solution 
was added drop-wise into DNA solutions and vortexed for about 30 seconds. Then the 
mixture was incubated at room temperature for over 30 minutes until the DNA/PEI 
complex forms.    
3.2.4 Characterization of PEI/DNA complex through Atomic force 
microscopy  
The size and surface morphology of the DNA/Polymer complexes were analyzed 
using atomic force microscopy (AFM) Nanoscope IV Bioscopet (Digital Instruments, 
Veeco) in tapping mode using a standard 125 µm silicon cantilevers (NCH tips, 
Nanosensors) and a resonance frequency of about 200 kHz. Scanning was performed 
at a scan speed of 0.5 Hz with a resolution of 512*512 pixels. Mica has been 
determined to be the substrate for imaging polyplexes because it is extremely flat (on 
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the scale of the size of the DNA molecule). Furthermore, Freshly-cleaved mica has a 
negative surface charge due to the presence of hydroxyl groups recessed slightly 
below the surface, with a spacing of 0.5 nm [30]. Thus, PEI25kd/DNA complex at 
N/P ratio (10:1) and chitosan/DNA complex (w/w 1:1) with positive charge can bind 
to mica surface directly. Discs of mica (SPI Supplies, STRUCTURE PROBE, and 
USA) were glued to steel disks with adhesives provided by Digital Instruments, and 
cleaved with adhesive tape immediately before use. 
 
3.2.5 In vitro gene transfer 
All cell lines mentioned above were used for the transfection experiment with the 
same method. The procedures are as follows. The cells were plated in 24-well plates 
at a cell density of 5*104 per well with 500μl medium described above one day prior 
to transfection. After one night of incubation, the culture medium of each well was 
replaced with 300μl Opti-MEM I Reduced Serum Medium (INVITROGEN) and 10μl 
PEI/DNA complex solution which contain 0.2μg DNA. TPGS with different 
concentration ranging from 0.04mg/ml to 0.4mg/ml was co-administered after the 
complex was added. All cells with the DNA/PEI complex were incubated for 48 hours 
at 37 oC. The transfecion efficiency of cells was indicated by calculating the amount 
of expressed b-galactosidase protein of each well. The protein was measured by using 
the High sensitivity β-galactosidase assay kit (STRATAGEN) according to the 




3.2.6 Quantitative study of cellular uptake of fluorescent polystyrene 
(PS) nanoparticles  
 
Caco-2 cells, MDCK and NIH 3T3 cells were used to investigate TPGS effect on the 
cellular uptake of PS nanoparticles. Cells were seeded in 96-well black plates (Costar, 
IL, USA) at a density of 5*103 cells per well. After overnight incubation, the culture 
medium was equilibrated with HBSS buffer (Hank’s balanced salt solution, HBSS, 
pH 7.4) at 37 oC for 30 min. After equilibration, cell uptake of nanoparticles was 
initiated by exchanging the transport medium with 100 μL of specified nanoparticle 
suspension (100 mg/mL in HBSS). Cells were then divided into three groups among 
which two groups mediated by 0.0005% TPGS and 0.001% TPGS solution while the 
left one acted as the control. After that, the cells were incubated at 37 oC for 4 h. The 
experiment was terminated by washing the cell monolayer three times with 
phosphate-buffered saline (PBS, pH 7.4) to eliminate excess particles which were not 
encapsulated by the cells. After that, cells were lysed with 0.5% Triton X-100 in 0.2N 
NaOH solution to expose the internalized nanoparticles for the quantitative 
measurement. Cell-associated nanoparticles were quantified by analyzing the cell 
lysate in a SafireII microplate reader (Tecan, Ma¨ nnedorf, Switzerland, lex430nm, 
lem 485 nm). Uptake efficiency of the nanoparticles was expressed as the percentage 




3.2.7 Cell viability assay 
Three cell lines mentioned above were plated at a density of 5*103 per well in 96-well 
microtiter plates (NUNC, Germany). After overnight incubation, culture medium was 
replaced with fresh medium containing PEI/DNA complex blended with TPGS or 
PEI/TPGS only with different concentrations. Cell with these supplements were then 
incubated for 48 hours. For cell viability assay, 20μl MTS tetrazolium compound 
reaction solution [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium] and 4.8 μl Phenazine methosulfate (PMS)) was directly 
added to each sample well.  Samples were incubated with the reagent for 1 h in the 
CO2 incubator at 37 °C. Absorbance was measured at 490 nm using Genios Micro 
plate reader at 260 nm (Tecan, Mannedorf, Australia). Quintuplicate determinations 
for each treatment were performed. The relative cell viability of sample related to 
control cells without adding anything was indicted by calculating the ratio of two 
absorbance values.  
 
3.2.8 Confocal laser scanning microscopy 
Here we used confocal laser scanning microscopy to visualize the GFP expression in 
cells. MDCK cells were seeded on 24*24mm cover slips at 7*104 cells/cm2 density. 
The cells were transfected with TPGS mixed complexes prepared in basal DMEM. 
Control cells were untreated and maintained in basal DMEM without DNA alone or 
DNA/PEI complexes. After the transfection for 24 h, the cells were rinsed with PBS 
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and observed using confocal microscopy (Olympus TCS NT, Leica Microsystems, 
Wetzlar, Germany) equipped with a 75mW argon/krypton laser (Omnichrome, Chino, 
































Chapter 4 Results and Discussion 
4.1 Nanoparticles for RNAi delivery 
4.1.1 Preparation and particle size effect 
Here we studied two nanoparticles preparation methods nanoprecipitation method and 
solvent evaporation technique, and the factors which affect the particle size during the 
formulation process.  Particle size has been demonstrated to play an important role in 
determining the level of cellular and tissue uptake, thus it will directly affect the 
transfection efficiency of dsRNA. People have studied the effect of the particle size 
on the caco-2 uptake and found that the optimum size range for caco-2 cellular uptake 
of nanoparticles is 100–200 nm [187]. Another research has also been conducted to 
investigate the size effect on the gene transfection efficiency and PLGA nanoparticles 
with smaller size below 100nm tend to gain higher gene transfection efficiency than 
those of 200nm [188].  
 
MPEG-PLA copolymer was a gift from Dr. Wan Yuqing of chemotherapy lab NUS 
with the average molecular weight being 62,500 and the weight content of MPEG 
being 10%. The PLGA/PEI and MPEG-PLA/PEI nanoparticles were prepared by a 
nanoprecipitation method [184, 189, 190]. Here PEI 25kd was used to be the 
surfactant in the water phase with the concentration of 100mg/ml to facilitate the 
polymers in the oil phase to form the stable nanoparticles, while people tend to use 
Pluronic F-68 as the surfactant t o avoid the aggregation of the nanoparticles [184] . 
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The other purpose of PEI25kd used here is to modify the nanoparticles into cationic 
surface to facilitate the loading of negatively charged dsRNA. Several concentrations 
of PEI 25kd (10mg/ml-100mg/ml) were tested and it can be seen that different 
concentrations of the surfactant PEI 25kd will not affect the size of the prepared 
nanoparticles. Here we use the excessive PEI 25kd (100mg/ml) to make the 
nanoparticles surface fully coated by the surfactant to change their surface charge. 
From the data in Table 4.1, it can be seen that coating with PEI 25kd increases the 
particle size for about 50 to 70nm comparable to the pure PLGA nanoparticles and 
MPEG-PLA nanoparticles without any surfactant. Nanoprecipitation method had also 
been used to formulate the PLGA/chitosan nanoparticles and MPEG/PLA 
nanoparticles and the particle size are rather large at 500-800 nm (data not shown) 
because the water phase formed by the chitosan acetic acid solution is very sticky 
which might have increased the water phase viscosity and tend to make the PLGA/ 
chitosan nanoparticles aggregate. Here we can see that in the nanoprecipitation 
method the particles size depends not only on the organic phase viscosity [184] but 
also the water phase viscosity. The less viscous organic and water phase tends to 
produce the smaller particles. As a result, the PLGA/chitosan nanoparticles and 
MPEG-PLA/chitosan nanoparticles were finally prepared using the solvent 
evaporation technique. Chitosan dissolved in the acetic solution acted as the co 
emulsifier with the PVA to stabilize the formation of the nanoparticles.   
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The ratio of chitosan to PVA was optimally adjusted to produce uniform cationic 
nanoparticles because too much chitosan (more than 500mg) added would increase 
the particle size of the nanoparticles significantly, while too less chitosan (less than 
100mg) would not modify the surface of the nanoparticles in a homogenous way. The 
polydispersity value in Table4.1 demonstrates that the spherical nanoparticles 
formulated by this solvent evaporation technique takes advantage over the traditional 
emulsion solvent evaporation methods which produced heterogeneous size distributed 
nanoparticles which researchers previously used to load the plasmid DNA. 
  
4.1.2 Surface morphology and zeta potential of the nanoparticles  
The particles under FESEM investigation as shown in Fig 4.1 show its sub-cellular 
size and spherical shape. The particle sizes of four nanoparticles are measured by the 
laser light scattering technique indicated as the effective diameters (Table 4.1). From 
the SEM image we can estimate that the nanoparticles are in their sub-micron size and 
the dynamic laser light assay further proved this point as shown in Table 4.1, where 
the effective diameter of nanoparticles are in the range of 100nm and 300nm.  The 
surface charge of the nanoparticle delivery system is one of the important factors 
affecting the loading efficiency of dsRNA and was determined by the amount of the 
nitrogen group of PEI 25kd and the chitosan coated on the surface of the nanoparticles 
which can be seen in Fig 4.2.  The zeta potential of the nanoparticles significantly 
changed from negative to positive value as can be seen in Table 4.1 after being 
modified by the PEI25kd and chitosan so that the nanoparticles would effectively 
carry the negatively charged dsRNA by spontaneously forming the complex with it 
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through charge interaction. We further employed XPS to study the surface group of 
the nanoparticles and analyzed the quantity of the nitrogen element on the surface of 
each kind of nanoparticle. The PEI 25kd modified surface showed more nitrogen 
percentage of the nanoparticles comparable to the nanoparticles coated with chitosan. 
One possible reason might be that the nitrogen element percentage in PEI25kd 
(C2H5N) (32.5%) is higher than that in chitosan (C6H11O4N) (8.69%).  Another 
reason might attribute to the distribution of PVA on the surface of the PLGA/chitosan 
and MPEG-PLA/chitosan nanoparticles, which can not be totally removed during the 
wash away process[191, 192] and might affect the adherence of the chitosan to the 
core of the nanoparticles. According to the element percentage in Table 4.2, it can be 
seen that the nitrogen percentage of the PLGA nanoparticle is higher than the 
MPEG-PLA nanoparticles indicating that PLGA attracted more cationic surfactants 
than MPEG-PLA. This phenomenon also leads to the fact that both PLGA and 
MPEG-PLA nanoparticles coating with PEI 25kd get higher zeta potential value than 
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Fig.4.1. FESEM images of polymeric nanoparticles. A) MPEG-PLA/PEI 
nanoparticles. B) PLGA/chitosan nanoparticles. C) PLGA/PEI nanoparticles D) 












Table 4.1 Size, zeta potential, of PLGA and MPEG-PLA nanoparticles with PEI25kd 
and chitosan surface modified   
 




Effective Diameter (nm)  88.9nm 226.7 164.6 
Polydispersity 0.116 0.152 0.154 


















 PLGA PLGA chitosan PLGA PEI 25kd 
Effective Diameter (nm) 147.6 260.5 200.3 
Polydispersity 0.061 0.203 0.123 













Fig 4.2 XPS spectrum of PLGA nanoparticles with PEI25kd coating a. the whole 




Table.4.2 XPS analysis of surface element of PLGA nanoparticles and MPEG-PLA 
nanoparticles with PEI 25kd and chitosan as the surfactants  
 
4.1.3 Gel Retardation assay  
The complexation of dsRNA with the nanoparticles was determined from the gel 
retardation assay. PLGA/PEI Nanoparticles form complex with dsRNA when their 
ratio is above 6:1 (w/w) as shown in Fig 4.2A. Here all of the four nanoparticles 
shows great potential in loading the dsRNA. This further confirmed the previous 
result that nanoparticles through polycations modification can absorb the negative 
charge nucleic acid and load it efficiently[193]. The charge interaction is also firm 
enough to absorb the dsRNA at the surface of nanoparticles. This result also coincided 
with the zeta-potential results and the XPS studies of the surface of nanoparticles. 
This further confirmed that the adsorption of dsRNA on the surface of the various 
nanoparticles largely depended on the quantity of the nitrogen groups and also 
indicates that PLGA/PEI acquires better dsRNA loading capacity than all the other 
three nanoparticles.  
 
Atomic MassConcentration (%) C N O 
PLGA &Chitosan 66.41% 1.04%   39.12% 
PLGA&PEI25kd 60.36% 8.97% 30.67% 
MPEG-PLA &Chitosan 49.47% 0.65% 49.88%    
MPEG-PLA&PEI25kd 55.96%       2.00% 42.04% 
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             1   2    3    4    5    6                   1    2    3   4        5 
(A)  (B)  
Fig.4.3 Gel electrophoresis of the RNA and nanoparticles (A) PLGA/PEI 
nanoparticles blending with RNA at different ratio (1-5) 3µg dsRNA: nanoparticle 
complexed with RNA (the amounts of the PLGA/PEI nanoparticles were 100, 50, 20, 
10 and 4µg, respectively (6) 3µg dsRNA (B) MPEG-PLA/chitosan, MPEG-PLA/PEI 
nanoparticles, PLGA/Chitosan, PLGA/PEI nanoparticles. (1-4) 1µg dsRNA with 50ug 
nanoparticle complex (5) 1ug dsRNA 
 
4.1.4 Inhibition of HBsAg expression 
 
PLC/PRF/5 [192] cell line which can constitutively produce and secret hepatitis B 
antigen (HBsAg) were used for the cell experiment. PLC/PRF/5 here acted as the 
diseased cell line model to simulate the infected liver cells which can continuously 
produce and secret hepatitis B antigen. S2RNA is designed to inhibit the expression of 
HBsAg. According to the previous research done by Li. et al [185], the S2RNA we 
used have been demonstrated to inhibit the HBsAg expression effectively delivered 
by the transfection agent lipofectamine 2000. Therefore, efficient delivery of HBsAg 
to the cells will eventually lead to the decreased HBsAg expression level by the 
PLC/PRF/5 cell lines. In order to assess the delivery efficiency of our system, we 
studied the inhibition effect of S2RNA delivered by our cationic system. Here we 
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evaluate the transfection efficiency by calculating the percentage of HBsAg 
expression level of the treated cell well to the untreated cell well. Higher transfection 
efficiency also means effective treatment is supposed to lead to lower HBsAg 
expression level.  
 
The concentration of S2RNA we used is 0.2µM because it is suggested as the most 
effective concentration [194]. The amount of nanoparticles we used is 200µg/ml 
which is more than 50 times the amount of S2RNA in order to completely condense 
the S2RNA. After 48 hours following treatment of PLC/PRF/5 cells with the 
S2RNA/nanoparticles complex, an obvious decrease of expression of HBsAg was 
observed in each group of this nanoparticles mediated transfection. This suggested 
that the S2RNA was efficiently delivered into the cells so that it could effectively 
inhibit the secretion of the HBsAg by the PLC/PRF/5 cells.  
 
As shown in Fig 4.3, Lipofectamine showed more than 80% decrease of the HBsAg 
expression. The expression levels of four groups of cells treated by 
nanoparticles/RNA complex (PLGA/chitosan, MPEG-PLA/chitosan, PLGA/PEI, 
MPEG-PLA/ PEI) are 42.50%, 44.80%, 24.26%, 19.66% respectively. All of those 
nanoparticles showed efficient delivery of the RNA. Among all the four nanoparticles, 
MPEG-PLA/PEI nanoparticles mediated RNA transfection demonstrated the best 
inhibition effect, which suggested that MPEG-PLA/PEI might be of the greatest 
potential to act as the delivery system.  
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Fig.4.4 Effects of SiRNA carried by four nanoparticles in PLC/PRF/5 cells .From left 
to right: (1). pure cells untreated with siRNA; (2). cells treated with lipofectamine 
delivered siRNA; (3-6) cells treated with four nanoparticles delivered siRNA 
 
4.1.5 Cell viability assay 
The cytotoxicity of the four nanoparticles was estimated by the MTS assay. The cell 
viabilities of nanoparticles were 94.55%, 105.93%, 92.85%, 95.81% respectively. All 
of the values are in excess of 90%, indicating the delivery system are more 
biocompatible and safer than lipofectamine comparing to the lower cell viability of 
lipofectamine (72.42%) as shown in Fig 4.4. This result further demonstrated that the 











Cationic nanoparticles combined the advantages of nanoparticles as a drug carrier and 
the complexation ability with nucleic acid in acting as the gene carrier. With better 
biocompatibility and easy producing property, cationic nanoparticles have gained 
more and more attention in the gene delivery area. Unlike the delivery of plasmid 
DNA, the transport of dsRNA is much easier since there is no need to deliver the 
dsRNA into the cell nucleus [194] and the barrier for the dsRNA is less. Thus, dsRNA 
is more like a kind of drug than the traditional gene therapy method. Therefore, the 
loading efficiency of this drug is very important for the delivery system. 
 
Previous polymeric nanoparticles mediated gene delivery method tend to use double 
emulsion technique loading the therapeutic gene and was limited by the low 
encapsulation efficiency of the drug. Moreover, during the process of preparing 
nanoparticles through double emulsion technique, the contact of the dsRNA with a lot 
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of organic solvent and the involvement of sonication procedure might damage or 
denature the dsRNA. Now more and more researchers employ the cationic 
nanoparticles simply because it is an easy, safe and efficient way to carry the 
therapeutic drug. In this thesis, we adopted a strategy where the cationic polymer was 
surface-absorbed PLGA or MPEG-PLA nanoparticles and the RNA would 
subsequently coat on the surface of the nanoparticles to form the “layer-by-layer” 
approach [22]. 
 
We chose chitosan and PEI as our nanoparticles coating regents simply because they 
are two mostly used polycationic polymers for the current gene therapy. Many 
comparisons[22, 117] have ever been done between the two polymers to evaluate 
their potential as the non-viral gene delivery vector and no agreement have been made 
since they have different delivery properties and different structural characteristics.  
 
Our results show that PEI 25kd is slightly better than the chitosan by showing higher 
gene transfection efficiency and higher loading efficiency of RNA. It might be due to 
two reasons. One is due to PEI 25kd has rich density of nitrogen groups to attract the 
dsRNA. The other reason is that nanoparticles coating with PEI 25kd is much smaller 
than those modified by the chitosan. And the latter also agree that the delivery of RNA 
is in a size dependency manner. The smaller the particle is, the higher transfection 
efficiency would be.  
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Another advantage of nanoparticles formulated by the nanoprecipitation method is the 
avoidance of the use of the surfactant such as PVA which has been considered to 
cause side effect and the usage of PEI as the surfactant not only play an important role 
in bind the RNA but also lower the interfacial energy at the established water/polymer 
interface, which facilitate the formation of small size of nanoparticles [195]. 
 
In conclusion, the cationic nanoparticles can act as an efficient delivery system for 
dsRNA. PEI 25kd coating yielded the more positively charged nanoparticles with the 
higher DNA binding capacity and higher in vitro transfection efficiency. MPEG-PLA/ 
PEI nanoparticles with the smallest size showed highest transfection efficiency. Future 
work will mainly be focused on the in vivo application of these gene delivery 
systems. 
 
4.3 TPGS enhancement for gene transfection efficiency 
4.3.1 Particle size  
From the AFM image Fig 4.6, we can estimate the size for PEI25kd&DNA complex 
here to be approximately in the range of 100nm to 200nm and spherical in shape. 
When the N/P ratio of PEI and DNA equals 10:1, the plasmid DNA can be completely 
condensed into a sphere by the branched PEI. It confirms the results previously 
demonstrated by others. And we can also show that TPGS blending with PEI/DNA 
complex would not affect their size and surface morphology.    
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Fig.4.6 AFM image: height of PEI25kd/DNA complexes (N/P ratio=10:1) 
 
4.3.2 PEI-25kd mediated in vitro gene delivery co administered with 
TPGS 
Here we examined the transfection efficiency in the serum free condition in several 
cell lines. TPGS was added by several concentrations from 0.01mg/ml to 0.05mg/ml 
per well. The concentration of PEI used is according to the N/P ratio (10:1). Complex 
without TPGS acted as the control. The results in Fig 4.7 shows that certain amount of 
TPGS was found to improve the transfection efficiency compared to the non TPGS 
added cells. The enhancement not only depended on TPGS concentration, but also 
cell types. MDCK cells showed a higher improvement rate as the TPGS concentration 
increased, while we can hardly find any significant improvement in NIH3T3 cell lines. 
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Here we demonstrated a simple and convenient method by simply co administering 
TPGS with the PEI/DNA complex to improve gene transfection efficiency. The 
mechanism on how TPGS inhibit P-gp protein need to be further studied.    






























Fig.4.7TPGS enhancement of PEI 25kd mediated gene transfection for MDCK cell 
lines 
 
4.3.3 Cellular Uptake Enhancement mediated by TPGS 
 
Fluorescently or radioactively labeled nanoparticles is the most common experimental 
approach applied by the previous researchers in order to study cellular uptake of 
nanoparticles. Fluorescent labeling was chosen for the present study to avoid exposure 
of the samples to radioactive materials. Standard fluorescent polystyrene 
nanoparticles with various sizes from 50nm-500nm were utilized to study the effect of 
TPGS mediated cellular uptake of nanoparticles. Fluorescent labeling makes cellular 
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uptake of nanoparticles readily detectable by fluorescence microscopy or CLSM. The 
extent of particle uptake can then be determined by quantitative extraction of the 
markers from the cells which can be measured by the micro plate reader [196]. Fig.4.8 
shows that TPGS can enhance the MDCK and CACO2 cellular uptake percentage of 
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Fig.4.8 Effect of TPGS enhancement on cellular uptake by (A)MDCK(B) CACO2, (C) 
NIH3T3 cells of polystyrene nanoparticles with various sizes after 4 h incubation at 
particle concentration of 0.1 mg/mL at 37 0C. The series of column A are results of 
pure polystyrene nanoparticles treated cells. Column B are results of polystyrene 
nanoparticles blended with 0.5% TPGS treated cells. Column C are results of 
polystyrene nanoparticles blended with 1% TPGS treated cells. Data represents 
mean±SD, n=3 
 
4.3.4 Cytotoxicity of TPGS co administered PEI 25kd 
 
TPGS is known to increase the cellular uptake of PEI/DNA complex, thus increase the 
transfection efficiency. Here we used the MTS assay to study the cell cytotoxicity of 
PEI/DNA complex mediated with TPGS at different concentrations for the MDCK 
cell line. The cell proliferation assay data show that as the amount of co administrated 
TPGS might slightly increased, the cytotoxicity of PEI25kd/DNA complex also 
increased, while the increased amount of TPGS itself would not affect the cell 
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TPGS blended PEI/DNA nanoparticle TPGS TPGS/PEI 
 
                          (B) 
Fig. 4.9 Cell cytotoxicity assay of TPGS mediated PEI/DNA complex (A). MTS assay 
of MDCK cells proliferation rate under various TPGS concentration (B) MTS assay 





4.3.5 GFP expression in MDCK cell line 
 
In Fig.4.10, we show confocal microscopic images of MDCK cells transfected by 
pCMV/NUC/GFP after 24 hours incubation, which strongly supported the previous 
quantitative measurements of the transfecion efficiency of pCMV/b-Gal by showing 
stronger fluorescence in the cell mediated with TPGS.  
A.                               B. 
 
Fig 4.10 GFP expression in MDCK cells after transfection. (A) MDCK cellscells were 
transfected with naked PEI/DNA complex mediated with 0.05mg/ml TPGS; (B) 




TPGS is already known to be a promising surfactant as well as a matrix material when 
blended with other biodegradable polymers due to its amphiphilic property [197], thus 
it has great advantages for the manufacture of polymeric nanoparticles for controlled 
release of paclitaxel and other anti-cancer drugs. Its application in the drug delivery 
area is highly developed after researchers found another amazing point of TPGS, 
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acting as the inhibitor of the P-glycoprotein. This property renders its use for crossing 
some human barriers such as blood brain barrier (BBB) and gastrointestinal barrier 
(GI) since the barriers hinder the absorption of the anticancer drug and decrease the 
bioavailability. Biodegradable nanoparticles containing drugs manufactured with 
TPGS has been proved to be higher intracellular uptake efficiency especially for some 
P-glycoprotein expressing cell lines, for example, CACO2 and MDCK cell lines. Here 
we tried to understand the mechanism of the improvement in cellular uptake and try to 
apply this to the delivery of this plasmid DNA.  
 
Firstly, we studied how TPGS affect the cellular uptake of nanoparticles with various 
sizes.  The nanoparticles we used are the commercially available polystyrene 
nanoparticles containing fluorescence inside with various sizes ranging as 20nm, 
50nm, 100nm, 200nm and 500nm. TPGS shows obvious enhancement of cellular 
uptake for the MDCK cells and CACO2 cells, however there is no obvious effect for 
the NIH3T3 cells. This might attribute to the reason that the enhancement of TPGS is 
P-gp specific.  We still need to use western blot experiment to verify the 
concentrations of P-gp in the cell membrane of MDCK cell lines. Previous 
researchers have already showed that CACO2 cell lines have P-gp proteins whereas 
NIH3T3 cell lines do not have. Our cellular uptake result confirmed this point. These 
results further demonstrated that the enhancement behavior of TPGS might be related 
to the multiple drug resistant proteins.  
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We further study the property of our target complex-PEI/DNA complex; here we 
blended the complex suspension with the TPGS and transfected in the MDCK cell 
line. The ß-galactose expression level for the TPGS-mediated transfection group 
shows higher than the one without TPGS. The GFP expression in Fig 4.10 also shows 
an obvious enhancement of the TPGS mediated transfection efficiency. 
 
Cell cytotoxicity assay shows that TPGS might slightly affect the cytotoxicity of the 
PEI25kd/DNA complex to the transfected cells. As is known, TPGS itself is non toxic 
and, the reason that it slightly enhances the cytotoxicity of the PEI/DNA complex to 














Chapter 5 Conclusions and Recommendations 
In our current research, our results showed that the traditional double emulsion 
technique for the formulation of polymeric nanoparticles is not suitable for 
constructing RNAi delivery system; although it achieved good result in some plasmid 
DNA based control release system. The reason might be attributed to the contact of 
the sonicator with the RNA during the formulate process. Our strategy to formulation 
cationic nanoparticles omitted this weak point and avoided many factors which might 
damage the RNA. We also showed that cationic nanoparticles can act as an efficient 
delivery system for dsRNA. We also found that PEI 25kd coating yielded the more 
positively charged nanoparticles with the higher DNA binding capacity and higher in 
vitro transfection efficiency than chitosan. Among all the four types of cationic 
nanoparticles, MPEG-PLA/ PEI nanoparticles with the smallest size showed highest 
transfection efficiency. Our results also indicated that the utilization of emulsifier PVA 
might affect the cellular uptake of the RNA/nanoparticles, thus affect the transfection 
efficiency, which agree with the previous results done by others. 
 
In the second part of the thesis, we study the TPGS effect on the gene transfection 
efficiency, MDCK cells and CACO2 were used as a P-gp richly expressing cells to 
evaluate the cellular uptake of fluorescent polystyrene nanoparticles of standard size 
and the transfection efficiency of TPGS mediated PEI/DNA nanoparticles. Based on 
the fact that TPGS is capable of enhancing cellular uptake of various size 
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nanoparticles, we tried to apply it to the gene delivery process and demonstrate the co 
administration of vitamin E TPGS solution promote the cellular uptake of PEI/DNA 
nanoparticles, thus enhance the gene transfection efficiency especially for P-gp richly 
expressed cells. This study shows that TPGS might have great potential to improve 
the brain gene delivery system and oral gene delivery system. However, the specific 
mechanism that TPGS enhance the cellular uptake and transfection efficiency still 
remains unknown. 
 
In the future work, TPGS can be introduced to the delivery system for the RNAi 
based treatment for Hepatitis B virus. TPGS can be blended with polymeric 
nanoparticles by acting as the surfactant. TPGS-PLA co-polymers synthesized in our 
lab are also suggested to be applied to the gene delivery area. Furthermore, specific 
cellular uptake mechanism and the interaction between TPGS and P-gp are suggested 
to be done in order to provide more solution for cross the barriers inside the human 
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